<\/strong><\/span><\/h4>\n<\/strong><\/span><\/h4>\nProf. Dr. Daciana Elena Br\u0103ni\u0219teanu<\/strong><\/span>
Universitatea de Medicin\u0103 \u0219i Farmacie \u201cGrigore T. Popa\u201d Ia\u0219i
Spitalul Clinic Universitar CF Ia\u0219i<\/strong><\/span><\/h4>\n[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”4.16″ locked=”off” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.20.4″ hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]<\/p>\n
Simpozion SANDOZ<\/span>
\nInova\u021bie continu\u0103 \u00een managementul onicomicozei<\/span><\/p>\nSimpozion ACM<\/span>
\nHeliocare: foto-imunoprotec\u021bie dermatologic\u0103 3600 oral\u0103 \u0219i topic\u0103<\/span><\/p>\nSimpozion URIAGE<\/span>
\nPruriced cu patentul PAR-2 REGUL, inova\u021bia Uriage \u00eempotriva pruritului<\/span>
\nDaciana Elena Br\u0103ni\u0219teanu
\nUniversitatea de Medicin\u0103 \u0219i Farmacie \u201cGrigore T. Popa\u201d Ia\u0219i, Rom\u00e2nia
\nSpitalul Clinic Universitar CF Ia\u0219i, Rom\u00e2nia<\/p>\nCuvinte cheie: prurit, boli de piele, afec\u021biuni sistemice, hemato-oncologie, oncologie<\/p>\n
Pruritul este cel mai frecvent simptom \u00een dermatologie \u0219i se reg\u0103se\u0219te, de asemenea, \u0219i \u00een alte patologii din medicina intern\u0103, endocrinologie, hepatologie, oncologie etc.
\nAcest simptom are cauze fiziologice sau patologice, intensitate de la discret\u0103 la sever\u0103, durat\u0103 de la ocazional\u0103 la cronic\u0103 \u0219i poate afecta corpul localizat sau generalizat.
\nDeoarece este manifestat \u00eentr-o multitudine de afec\u021biuni, afect\u00e2nd calitatea vie\u021bii pacien\u021bilor, este bine de \u0219tiut c\u0103 exist\u0103 produse dermato-cosmetice care pot fi recomandate pentru a reduce pruritul, de sine st\u0103t\u0103tor sau \u00een asociere cu alte tratamente.
\nURIAGE a dezvoltat gama Pruriced, cu patentul inovator PAR-2 Regul, Calamin\u0103, Ap\u0103 Termal\u0103 Uriage \u0219i p\u00e2n\u0103 la 96% ingrediente de origine natural\u0103.
\nPatentul PAR-2 Regul moduleaz\u0103 receptorul PAR2 care se implicat \u00een ambele c\u0103i ale pruritului \u2013 histaminic\u0103 \u0219i non-histaminic\u0103. Astfel, reduce expresia substan\u021belor pruriginoase \u0219i reduce pruritul.
\nCalamina este cunoscut\u0103 pentru propriet\u0103\u021bile sale calmante, hidratante, antipruriginoase, purificatoare \u0219i revigorante.
\nApa Termal\u0103 Uriage este o ap\u0103 izotonic\u0103, filmogenic\u0103, bogat\u0103 \u00een minerale \u0219i oligoelemente, activ\u0103 \u0219i cu propriet\u0103\u021bi unice de hidratare, calmare, vindecare \u0219i refacere a barierei cutanate.
\nPruriced este disponibil \u00een 3 formate de produs, potrivit pentru recomandare \u00een diferite tipuri de patologii sau nevoi de \u00eengrijire:
\n\u2022 Pruriced Crem\u0103 Calmant\u0103 \u2013 pentru prurit localizat sau generalizat, pe piele f\u0103r\u0103 p\u0103r, precum \u0219i prurit \u00een condi\u021bii diverse asociat pielii uscate.
\n\u2022 Pruriced Gel Calmant \u2013 pentru prurit generalizat sau localizat, \u00een zone cu p\u0103r, pliuri, zone extinse \u0219i zone intime externe.
\n\u2022 Pruriced SOS dup\u0103 \u00een\u021bep\u0103turi de insecte.
\nToate produsele pot fi recomandate de la nou n\u0103scu\u021bi p\u00e2n\u0103 la pacien\u021bii v\u00e2rstnici, \u00een func\u021bie de patologie.<\/p>\n
Pruriced, with PAR-2 Regul patent, Uriage innovation against pruritus\/itching<\/span><\/p>\nDaciana Elena Br\u0103ni\u0219teanu
\nUniversity of Medicine and Pharmacy “Grigore T. Popa” Iasi, Romania
\nCF Iasi University Clinical Hospital, Romania<\/p>\n
Keywords: pruritus, skin diseases, systemic diseases, hemato-oncology, oncology<\/p>\n
Itching is the most common symptom in dermatology and is also found in other pathologies in internal medicine, endocrinology, hepatology, oncology, etc.
\nThis symptom has physiological or pathological causes, variable intensity from discrete to severe, variable duration from occasional to chronic, and can affect the body locally or entirely.
\nIt is present in a multitude of conditions, affecting patients\u2019 quality of life. This is why it is important to know that there are dermato-cosmetic products that can be recommended to reduce pruritus, alone or associated with other treatments.
\nURIAGE has developed the Pruriced range, with the innovative PAR-2 Regul patent, Calamine, Uriage Thermal Water and up to 96% ingredients of natural origin.
\nPAR-2 Regul patent modulates the PAR2 receptor involved in the 2 pathways of pruritus \u2013 histaminic and non-histaminic. Thus, it reduces the expression of pruritic substances and reduces itching.
\nCalamine is known for its soothing, moisturizing, antipruritic, purifying and invigorating properties.
\nUriage Thermal Water is an isotonic, filmogenic water, rich in minerals and trace elements, active and with unique properties of hydrating, calming, healing and restoring the skin barrier.
\nPruriced is available in 3 product formats, suitable for recommendation in different types of pathologies or care needs:
\n\u2022 Pruriced Soothing Cream \u2013 for localized or generalized itching, on skin without hair, as well as itching in various conditions associated with dry skin.
\n\u2022 Pruriced Soothing Gel \u2013 for generalized or localized itching, in areas with hair, folds, extended areas and external intimate areas.
\n\u2022 Pruriced SOS after insect bites.
\nAll products can be recommended to patients of different ages, from newborns to elderly ones, depending on the pathology.<\/p>\n
Simpozion SERVIER<\/span>
\nBoala Venoasa Cronic\u0103: dincolo de semne…<\/span><\/p>\nDaciana Elena Br\u0103ni\u0219teanu
\nUniversitatea de Medicin\u0103 \u0219i Farmacie \u201cGrigore T. Popa\u201d Ia\u0219i, Rom\u00e2nia
\n\u015eef al Clinicii de Dermatologie, Spitalul Clinic CF Ia\u0219i, Rom\u00e2nia<\/p>\n
Cuvinte cheie: boala venoas\u0103 cronic\u0103, riscuri, medicamentul venoactiv de referin\u021b\u0103<\/p>\n
Este binecunoscut faptul c\u0103 Boala Venoas\u0103 Cronic\u0103 este o boal\u0103 progresiv\u0103 cu o prevalen\u021b\u0103 crescut\u0103 \u00een r\u00e2ndul popula\u021biei adulte. \u0218tim \u0219i pentru c\u0103, dincolo de datelele epidemiologice, diagnostic\u0103m un num\u0103r mare de pacien\u021bi \u00een practica medical\u0103 zilnic\u0103\u2026iar ceea ce putem observa sunt at\u00e2t semnele caracteristice bolii, c\u00e2t \u0219i afectarea calit\u0103\u021bii vie\u021bii pacien\u021bilor. Este important \u0219i s\u0103 afl\u0103m dac\u0103 dincolo de ceea ce este vizibil, sunt \u0219i riscuri la care pacien\u021bii cu Boal\u0103 Venoas\u0103 Cronic\u0103 sunt expu\u0219i. V\u0103 invit\u0103m s\u0103 participa\u021bi la eveniment pentru a descoperi toate acestea, dar \u0219i cum putem interveni eficient terapeutic!<\/p>\n
Chronic venous disease: beyond signs\u2026<\/span><\/p>\nDaciana Elena Br\u0103ni\u0219teanu
\nThe University of Medicine and Pharmacy \u201cGrigore T. Popa\u201d Iasi, Romania
\nHead of the Dermatology Clinic, CF Clinical Hospital Iasi, Romania<\/p>\n
Keywords: chronic venous disease, risks, the reference venoactive drug<\/p>\n
It is well known that Chronic Venous Disease is a progressive disease with an increased prevalence among the adult population. We also know because, beyond the epidemiological data, we diagnose a large number of patients in our daily medical practice…and what we can observe are both the characteristic signs of the disease and the impact on the patients’ quality of life. It is also important to find out if, beyond what is visible, there are also risks to which patients with Chronic Venous Disease are exposed. We invite you to take part in this event to discover all these, but also how we can effectively intervene therapeutically!<\/p>\n
SESIUNE \u015eTIIN\u0162IFIC\u0102 ORGANIZAT\u0102 CU SUS\u0162INEREA COMPANIEI TERAPIA<\/span>
\nLocul Ilumetri \u00een abordarea personalizat\u0103 a pacientului cu psoriazis<\/span><\/p>\nSESIUNE \u015eTIIN\u0162IFIC\u0102 ORGANIZAT\u0102 CU SUS\u0162INEREA COMPANIEI SANOFI<\/span>
\nDupixent \u2013 2 ani de success terapeutic \u00een Rom\u00e2nia<\/span><\/p>\nSESIUNE \u015eTIIN\u0162IFIC\u0102 ORGANIZAT\u0102 CU SUS\u0162INEREA COMPANIEI JANSSEN<\/span>
\nDiferen\u021bierile moleculare ale inhibitorilor IL-23 influen\u021beaz\u0103 r\u0103spunsul \u00een tratamentul psoriazisului<\/span><\/p>\nSimpozion NOVARTIS<\/span>
\nCOSENTYX \u2013 tratamentul complet al bolii psoriazice<\/span><\/p>\nSimpozion LILLY<\/span>
\nO nou\u0103 abordare terapeutic\u0103 oral\u0103 \u00een dermatita atopic\u0103 \u2013 inhibitorul Jak Olumiant<\/span><\/p>\nCodrina Ancu\u021ba1, Daciana Br\u0103ni\u0219teanu2, A. Nicolescu3
\n1U.M.F. \u201dGrigore T. Popa\u201d Reumatologie Ia\u0219i, Rom\u00e2nia
\n2U.M.F. \u201dGrigore T. Popa\u201d Dermatologie Ia\u0219i, Rom\u00e2nia
\n3Dermatologie Bucure\u0219ti, Rom\u00e2nia<\/p>\n
Cuvinte cheie: dermatit\u0103 atopic\u0103, imunomodula\u021bie, JAK(i), terapie oral\u0103, protocol terapeutic<\/p>\n
Misiunea noastr\u0103 \u00een imunologie este aceea de a \u00eembun\u0103t\u0103\u021bi via\u021ba pacien\u021bilor \u0219i consider\u0103m c\u0103 medicamentele noastre pot redefini op\u021biunile terapeutice \u00een psoriazis, dermatita atopic\u0103, artrita psoriazic\u0103, artrita reumatoid\u0103, spondiloartritele axiale, bolile inflamatorii intestinale, acest lucru \u00eensemn\u00e2nd ridicarea continu\u0103 a \u0219tachetei \u00een acest domeniu. Dermatita atopic\u0103 este una dintre cele mai frecvente afec\u021biuni cutanate, \u00eent\u00e2lnit\u0103 la p\u00e2n\u0103 la 20% dintre copii \u0219i la 2 \u2013 10% dintre adul\u021bi \u0219i are un caracter cronic, cu o evolu\u021bie recidivant\u0103. Tratamentul \u00een dermatita atopic\u0103 trebuie adaptat gradului de severitate, obiectivele principale fiind suprimarea inflama\u021biei \u0219i restabilirea func\u021biei de barier\u0103 \u0219i pielii. Este important de re\u021binut c\u0103 dermatita atopic\u0103 sever\u0103 poate fi tratat\u0103 cu medica\u021bie sistemic\u0103, conven\u021bional\u0103, biologic\u0103 sau sintetic\u0103-\u021bintit\u0103. Dintre moleculele sintetice-\u021bintite face parte \u0219i baricitinib, un inhibitor intra-celular al c\u0103ii JAK-STAT, cu o experien\u021b\u0103 semnificativ\u0103 \u00een reumatologie, \u00een indica\u021bia artrit\u0103 reumatoid\u0103, care \u00eencep\u00e2nd din anul 2020 este indicat \u0219i \u00een dermatita atopic\u0103 moderat\u0103 p\u00e2n\u0103 la sever\u0103 la pacien\u021bi adul\u021bi candida\u021bi pentru terapie sistemic\u0103.<\/p>\n
A New Approach of the Oral Treatment in Atopic Dermatitis \u2013 Olumiant, the JAK-inhibitor<\/span><\/p>\nCodrina Ancu\u021ba1, Daciana Br\u0103ni\u0219teanu2, A. Nicolescu3
\n1Rheumatology U.M.F. \u201dGrigore T. Popa\u201d Iasi, Romania
\n2Dermatology U.M.F. \u201dGrigore T. Popa\u201d Iasi, Romania
\n3Dermatology Bucharest, Romania<\/p>\n
Keywords: atopic dermatitis, immunomodulatory, JAK(i), oral therapy, therapeutic protocol<\/p>\n
Our mission in immunology is to improve the lives of patients and we believe that our drugs can redefine the therapeutic options in psoriasis, atopic dermatitis, psoriatic arthritis, rheumatoid arthritis, axial spondylarthritis, inflammatory bowel disease, which means continuously raising the bar.
\nAtopic dermatitis is one of the most common skin conditions, found in up to 20% of children and 2-10% of adults and has a chronic course, with a recurrent evolution. The treatment in atopic dermatitis must be adapted to the degree of severity, the main objectives being the suppression of inflammation and the restoration of the skin barrier function. It is important to note that severe atopic dermatitis can be treated with systemic, conventional, biological, or synthetic-targeted medication. Among the synthetic-targeted molecules is baricitinib, an intracellular inhibitor of the JAK-STAT pathway, with significant experience in rheumatology, in the indication of rheumatoid arthritis, which since 2020 is also indicated in moderate to severe atopic dermatitis in adult patients who are candidates for systemic therapy.<\/p>\n
Simpozion ABBVIE<\/span>
\nSkyrizi – viitorul \u00een psoriazis este acum!<\/span><\/p>\nDaciana Br\u0103ni\u0219teanu1, Carmen Curea2
\n1Sec\u021bia de Dermatovenerologie, Spitalul Clinic CF Ia\u0219i, Rom\u00e2nia
\n2Spitalul Clinic Colentina, Bucure\u0219ti, Rom\u00e2nia<\/p>\n
Psoriazisul este o boal\u0103 inflamatorie frecvent\u0103, cu comorbidit\u0103\u021bi semnificative, al c\u0103rei management poate fi dificil, av\u00e2nd \u00een vedere varietatea op\u021biunilor de tratament. Este esen\u021bial ca medicii s\u0103 aib\u0103 informa\u021bii utile despre tratamentul \u0219i monitorizarea pacien\u021bilor cu boal\u0103 psoriazic\u0103. De\u0219i anumite aspecte ale \u00eengrijirii se aplic\u0103 tuturor pacien\u021bilor, fiecare agent terapeutic are propriul s\u0103u profil cu impact direct \u00een ceea ce prive\u0219te evaluarea pacien\u021bilor, schema de administrare \u0219i monitorizarea. Alegerea tratamentului se bazeaz\u0103 nu numai pe severitatea bolii ci \u0219i pe comorbidit\u0103\u021bile \u0219i terapiile concomitente. Compania AbbVie va prezenta o solu\u021bie terapeutic\u0103 pentru managementul bolii psoriazice cu dovezi din studii clinice \u0219i date din via\u021ba real\u0103. Va fi detaliat mecanismul de ac\u021biune \u0219i cum influen\u021beaz\u0103 acesta rezultatele de eficacitate, durabilitate, siguran\u021b\u0103 \u0219i simplitate \u00een administrare.
\nDe asemenea se vor detalia date pe termen scurt \u0219i pe termen lung care ofer\u0103 o imagine a terapiilor avansate utilizate \u00een practica clinic\u0103 \u00een ceea ce prive\u0219te eficacitatea \u0219i tolerabilitatea.
\nNu \u00een ultimul r\u00e2nd, \u00een simpozionul Abbvie se vor eviden\u021bia aspecte practice legate de managementul terapeutic modern al pacien\u021bilor cu psoriazis moderat \u0219i sever.<\/p>\n
The Future in Psoriasis is Now!<\/span><\/p>\nDaciana Br\u0103ni\u0219teanu1, Carmen Curea2
\n1Department of Dermatovenerology, CF Iasi Clinical Hospital, Romania
\n2 Colentina Clinical Hospital, Bucharest, Romania<\/p>\n
Psoriasis is a common inflammatory disease with significant comorbidities, the management of which can be difficult given the variety of treatment options. It is essential for the physicians to have useful information about the treatment and monitoring of patients with psoriatic disease. Although certain aspects of care apply to all patients, each therapeutic agent has its own profile with direct impact on patient assessment, dosing schedule and monitoring. The choice of treatment is based not only on the severity of the disease but also on comorbidities and concomitant therapies. AbbVie will present a therapeutic solution for the management of psoriatic disease with clinical trial evidence and real-life data. The mechanism of action will be detailed and how it influences the results of effectiveness, durability, safety and simplicity in administration.
\nShort-term and long-term data that provide a picture of advanced therapies used in clinical practice in terms of efficacy and tolerability will be presented also.
\nLast but not least, the Abbvie symposium will highlight practical aspects related to the modern therapeutic management of patients with moderate and severe psoriasis.<\/p>\n
Simpozion ANTIBIOTICE<\/span>
\nBeneficiile de la A la Z pentru pacien\u021bii cu rozacee. Expertiza industriei farmaceutice rom\u00e2ne\u0219ti<\/span><\/p>\nDaciana Br\u0103ni\u015fteanu
\nU.M.F. \u201cGrigore T. Popa\u201d Ia\u015fi, Rom\u00e2nia<\/p>\n
Cuvinte cheie: rozacee, dermatocosmetice, acid azelaic<\/p>\n
Cu o expertiz\u0103 de peste 65 de ani \u00een formularea medicamentelor dermatologice, compania Antibiotice a inaugurat \u00een 2022 cea mai modern\u0103 fabric\u0103 de produse topice din Europa. \u00cen mod firesc, portofoliului de produse i s-a al\u0103turat \u00een 2023, o nou\u0103 linie de dermatocosmetice, Tinero\u00ae AZ, destinat\u0103 \u00eengrijirii de la A la Z a tenului cu rozacee.
\nUn aspect important \u00een strategia terapeutic\u0103 destinat\u0103 rozaceei \u00eel constituie asocierea produselor dermatocosmetice. Linia Tinero\u00ae AZ are un rol important \u00een managementul rozaceei, prin controlul seboreei, refacerea func\u0163iei de barier\u0103 epidermic\u0103, sc\u0103derea inflama\u0163iei \u0219i reducerea eritemului.
\nLinia Tinero\u00ae AZ con\u0163ine trei produse (spum\u0103 pentru cur\u0103\u0163area bl\u00e2nd\u0103 a tenului, ser, crem\u0103 cu factor de protec\u0163ie solar\u0103) pe baz\u0103 de acid azelaic, un constituent natural al tegumentului. Acesta are un rol important \u00een tratamentul rozaceei, \u00een principal prin ac\u0163iunea antiinflamatorie \u0219i antioxidant\u0103. Date din literatur\u0103 \u00eei atribuie \u0219i o ac\u0163iune \u00eempotriva bacilului Oleronius.
\nGhidul de diagnostic \u0219i tratament al rozaceei, elaborat de SRD \u00een 2022, stipuleaz\u0103 c\u0103 \u00een func\u0163ie de gradul de seboree sau de iritare al fe\u0163ei, putem recomanda produse
\ndermatocosmetice sub form\u0103 de spum\u0103 (pentru ten cu grad redus de seboree) \u0219i produse pentru aplica\u0163ii \u00een timpul zilei, care con\u0163in ingrediente cu rol fotoprotector. \u00cen ceea ce prive\u015fte compozi\u0163ia, ghidul recomand\u0103 ingrediente cu ac\u0163iune antiiritant\u0103 \u0219i antiinflamatorie precum glicirizatul dipotasic \u0219i ceramidele, \u00eent\u00e2lnite de asemenea \u00een produsele din linia Tinero\u00ae AZ.<\/p>\n
Benefits from A to Z for rosacea patients. Romanian pharmaceutical industry expertise<\/span><\/p>\nDaciana Br\u0103ni\u015fteanu
\nU.M.F. \u201cGrigore T. Popa\u201d Iasi, Romania<\/p>\n
Keywords: rosacea, cosmeceuticals, azelaic acid<\/p>\n
With an expertise of over 65 years in dermatological medicines formulation, Antibiotice opened in 2022 the most modern factory of topical products in Europe. Subsequently, the product portfolio welcomed in 2023 a new line of cosmeceuticals, Tinero\u00ae AZ, for the management of rosacea, from A to Z.
\nAn important aspect in rosacea therapeutic strategy is adding cosmeceuticals in therapeutical algorithm. Tinero\u00ae AZ line has an important role in the management of rosacea, by controlling seborrhea, restoring the epidermal barrier function, reducing inflammation and reducing erythema.
\nTinero\u00ae AZ line contains three products (foam for skin\u2019s gentle cleansing, serum and SPF hydrating cream) based on azelaic acid, a natural constituent of the skin. It has an important role in the treatment of rosacea, mainly through its anti-inflammatory and antioxidant action. It is also cited in literature azelaic acid\u2019s action against the Oleronius bacillus.
\nThe rosacea diagnosis and treatment guide, developed by the Romanian Dermatology Society in 2022, stipulates that depending on the degree of seborrhea or facial irritation, we can recommend cosmeceuticals like foam (for a low degree of seborrhea skin) and products for daytime applications, which contain ingredients with a photoprotective role. Regarding the composition, the guide recommends as well ingredients with anti-irritant and anti-inflammatory action such as dipotassium glycyrrhizate and ceramides which are also found Tinero\u00ae AZ line.<\/p>\n
Simpozion UCB<\/span>
\nBimzelx transform\u0103 visul de PASI 100 \u00een realitate<\/span><\/p>\nSESIUNE \u015eTIIN\u0162IFIC\u0102 ORGANIZAT\u0102 CU SUS\u0162INEREA COMPANIEI JANSSEN<\/span>
\nA GUIDE to early intervention and disease modification in psoriasis<\/span><\/p>\nSESIUNE \u015eTIIN\u0162IFIC\u0102 ORGANIZAT\u0102 CU SUS\u0162INEREA COMPANIEI ABBVIE<\/span>
\nProvoc\u0103ri \u00een dermatologia clinic\u0103 – focus \u00een dermatita atopic\u0103 \u0219i psoriazis<\/span><\/p>\nSimpozion LILLY<\/span>
\nSesiune de discu\u021bii: dermatita atopic\u0103 la adult \u2013 diagnostic \u0219i tratament<\/span><\/p>\nModerator: Daciana Br\u0103ni\u0219teanu3
\nSpeakeri: Carmen Curea1, A. Nicolescu2
\n1Spitalul Colentina Dermatologie Bucure\u0219ti, Rom\u00e2nia
\n2Dermatologie Bucure\u0219ti, Rom\u00e2nia
\n3U.M.F. \u201dGrigore T. Popa\u201d Dermatologie Ia\u0219i, Rom\u00e2nia<\/p>\n
Cuvinte cheie: protocol terapeutic, dermatit\u0103 atopic\u0103 la adul\u021bi, terapie oral\u0103<\/p>\n
Dermatita atopic\u0103 este mai mult dec\u00e2t o boal\u0103 a pielii, av\u00e2nd o dubl\u0103 dimensiune \u2013 o latur\u0103 medical\u0103 \u0219i o latur\u0103 social\u0103 sau de integrare. Dermatita atopic\u0103 este caracterizat\u0103 \u00een primul r\u00e2nd printr-un prurit excesiv, ceea ce impacteaz\u0103 cov\u0103r\u0219itor calitatea vie\u021bii pacien\u021bilor. Dermatit\u0103 atopic\u0103 netratat\u0103 se poate asocia foarte frecvent cu boli grave, dar \u0219i cu afectarea calit\u0103\u021bii vie\u021bii pacien\u021bilor, apari\u021bia absenteismului, prezenteismului \u0219i tulbur\u0103ri anxios-depresive. Diagnosticarea corect\u0103, inclusiv \u00eencadrarea \u00een gradul de severitate potrivit poate conduce la instituirea tratamentului adecvat \u0219i la \u00eembun\u0103t\u0103\u021birea prognosticului evolutiv pe termen lung. Aceasta este cu at\u00e2t mai important\u0103 \u00een contextul noilor terapii, unde alegerea trebuie individualizat\u0103 fiec\u0103rui pacient. Ideal, aceast\u0103 alegere ar trebui s\u0103 se bazeze pe caracteristicile \u0219tiin\u021bifice ale tratamentelor \u0219i nevoile individuale \u0219i mai pu\u021bin pe considerente de acces. \u00cen acest sens, rolul protocolului terapeutic este esen\u021bial \u00een permiterea accesului la terapia inovatoare rambursat\u0103 \u0219i la minimizarea considerentelor de acces din decizia medical\u0103.<\/p>\n
Open Discussion: Atopic Dermatitis in Adult Patients \u2013 Diagnostic and Therapy<\/span><\/p>\nModerator: Daciana Br\u0103ni\u0219teanu3
\nCarmen Curea1, A. Nicolescu2
\n1Dermatology Colentina Hospital Bucharest, Romania
\n2Dermatology Bucharest, Romania
\n3Dermatology U.M.F. \u201dGrigore T. Popa\u201d Iasi, Romania<\/p>\n
Atopic Dermatitis is more than a skin disease, having a dual dimension \u2013 a medical one and a social integration issue, as well. Atopic Dermatitis is characterised by an intense pruritus that impacts patient quality of life. Untreated Atopic Dermatitis can associate with other severe diseases, and also with depreciated QoL; presenteeism, absenteeism and depressive disorders. Correct diagnostic and severity measurement can lead to correct treatment initiations and improved prognosis on the longer term. This is even more important in the context of novel therapies and personalised treatment decisions are needed. Ideally, this treatment decisions must rely more on scientific, medical treatment and patient characteristics and less on access schemes. Therefore, the role of the therapeutic protocol is essential for the access to innovative reimbursed medicines, with minimal impact on the pharmaco-economic side.<\/p>\n
Simpozion AVENE<\/span>
\nTriAsorb – a ultra broad spectrum filter covering UVB UVA & HEV blue light up to 450nm<\/span><\/p>\nScurt CV<\/span><\/p>\n\u2013 Profesor universitar, titular de curs de dermatologie, Facultatea de Medicin\u0103, U.M.F. \u201cGrigore T. Popa\u201d, Ia\u0219i
\n\u2013 Doctor \u00een \u0219tiin\u021be medicale, teza de doctorat \u00een ACNEEA VULGARA (2004)
\n\u2013 Manager al Centrului de Dermatologie, Venerologie \u0219i Dermatocosmetologie \u201cDermaLux\u201d, din 2004 p\u00e2n\u0103 \u00een prezent
\n\u2013 \u0218ef sec\u021bie la Clinica Dermatologic\u0103 a Spitalului Clinic C\u0103i Ferate Ia\u0219i
\n\u2013 Competen\u021be \u00een anatomie patologic\u0103 cutanat\u0103 (Lyon, Fran\u021ba) \u0219i \u00een dermatocosmetologie
\n\u2013 Cursuri de supraspecializare \u00een Fran\u021ba, Lyon, Universite Lyon 2 (AFSA), cursuri europene de dermatoscopie, boala venoas\u0103 cronic\u0103, psoriazis, anti-aging, injectare de filere, laserterapie etc.
\n\u2013 Preocup\u0103ri deosebite pentru psoriazis: coordonator al Proiectului Na\u021bional Educa\u021bional \u201cPatologia psoriazisului\u201d, particip\u0103ri \u00een calitate de expert la \u00eent\u00e2lniri interna\u021bionale pe teme de psoriazis (Viena, Atena, Geneva etc.), articole publicate \u00een reviste na\u021bionale \u0219i interna\u021bionale, comunic\u0103ri orale, conferin\u021be, grupuri de lucru \u0219i workshop-uri pe tema psoriazisului
\n\u2013 Pre\u0219edinte al Asocia\u021biei Dermatologilor din Moldova, Pre\u0219edinte al manifest\u0103rii na\u021bionale cu participare interna\u021bional\u0103 \u201cPrim\u0103vara Dermatologic\u0103 Ie\u0219ean\u0103\u201d;
\n\u2013 Membru \u00een Comitetul Director al Societ\u0103\u021bii Rom\u00e2ne de Dermatologie
\n\u2013 Membru \u00een Grupul Interna\u021bional \u201cMedical Reporter\u2019s Academy\u201d, pe probleme de flebologie
\n\u2013 Membru al: Academiei Europene de Dermatologie, Academiei Americane de Dermatologie, Societ\u0103\u021bii Franceze de Dermatologie, Societ\u0103\u021bii Franceze de Flebologie, Societ\u0103\u021bii Interna\u021bionale de Dermatologie, Societ\u0103\u021bii de Dermatologie Investigativ\u0103, Societ\u0103\u021bii Rom\u00e2ne de Dermatopediatrie, Societ\u0103\u021bii Rom\u00e2ne de Dermatoimunologie, Societ\u0103\u021bii de Medici \u0219i Naturali\u0219ti
\n\u2013 Coordonator a peste 100 de cursuri de educa\u021bie medical\u0103 continu\u0103 \u0219i de cursuri postuniversitare
\n\u2013 Peste 400 de conferin\u021be, prelegeri \u0219i comunic\u0103ri orale sus\u021binute la manifest\u0103ri \u0219tiin\u021bifice, mese rotunde, conferin\u021be \u0219i congrese din \u021bar\u0103, nu doar de dermatologie
\n\u2013 Lector invitat la Congrese Interna\u021bionale ale: Societ\u0103\u021bii Europene de Dermatologie \u0219i Venerologie (EADV), Societ\u0103\u021bii Franceze de Flebologie (SFP), Uniunii Interna\u021bionale de Flebologie (UIP)
\n\u2013 Expert \u00een Boala Venoas\u0103 Cronic\u0103, \u00een Maladii Transmisibile Sexual, expert dermatolog \u00een solu\u021bionarea unor cazuri medico-legale
\n\u2013 Decan de Serie desemnat de c\u0103tre studen\u021bi, ca semn de respect \u0219i de recunoa\u0219tere a calit\u0103\u021bii de dasc\u0103l
\n\u2013 Implicare activ\u0103 \u00een activitatea de cercetare \u0219tiin\u021bific\u0103 (granturi de cercetare \u0219tiin\u021bific\u0103, proiecte na\u021bionale \u0219i interna\u021bionale, studii clinice, consultant \u0219tiin\u021bific, membru \u00een numeroase advisory board-uri etc.)
\n\u2013 Peste 230 de lucr\u0103ri publicate \u00een \u021bar\u0103 \u0219i \u00een str\u0103in\u0103tate, autoare a 23 c\u0103r\u021bi \u0219i capitole de c\u0103r\u021bi de dermatologie
\n\u2013 Absolvent\u0103 a Facult\u0103\u021bii de Medicin\u0103, U.M.F. \u201cGrigore T. Popa\u201d, Ia\u0219i, promo\u021bia 1991<\/p>\n
[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.19.4″ background_color=”rgba(240,98,42,0.19)” background_image=”https:\/\/pdi.ro\/2023\/wp-content\/uploads\/2022\/12\/PDI2023_header__-scaled.jpg” background_blend=”multiply” custom_padding=”54px|0px|0|0px|false|false” top_divider_style=”waves2″ top_divider_color=”#ffffff” top_divider_height=”155px” top_divider_height_tablet=”” top_divider_height_phone=”97px” top_divider_height_last_edited=”on|desktop” bottom_divider_style=”waves2″ bottom_divider_color=”#F0622A” bottom_divider_flip=”vertical” bottom_divider_height_tablet=”” bottom_divider_height_phone=”59px” bottom_divider_height_last_edited=”on|desktop” global_module=”9177″ saved_tabs=”all” global_colors_info=”{}”][et_pb_row column_structure=”3_5,2_5″ _builder_version=”4.19.4″ custom_padding=”100px|0px|69px|0px|false|false” global_colors_info=”{}”][et_pb_column type=”3_5″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text disabled_on=”off|off|off” _builder_version=”4.20.2″ text_font=”Kaushan Script||||||||” text_text_color=”#f0622a” text_font_size=”30px” text_line_height=”1.2em” header_font=”||||||||” background_layout=”dark” text_font_size_tablet=”” text_font_size_phone=”” text_font_size_last_edited=”on|desktop” global_colors_info=”{}”]<\/p>\n
Contacteaz\u0103 operatorul PDI 2023<\/p>\n
[\/et_pb_text][et_pb_contact_form email=”contact@pdi.ro” submit_button_text=”Trimite mesajul” disabled_on=”off|off|off” _builder_version=”4.20.2″ _unique_id=”794aaef5-e005-432a-99fb-9ca53e06d67b” title_font=”||||||||” custom_button=”on” button_text_color=”#F0622A” global_colors_info=”{}”][et_pb_contact_field field_id=”Name” field_title=”Nume” _builder_version=”4.16″ global_colors_info=”{}” button_text_size__hover_enabled=”off” button_one_text_size__hover_enabled=”off” button_two_text_size__hover_enabled=”off” button_text_color__hover_enabled=”off” button_one_text_color__hover_enabled=”off” button_two_text_color__hover_enabled=”off” button_border_width__hover_enabled=”off” button_one_border_width__hover_enabled=”off” button_two_border_width__hover_enabled=”off” button_border_color__hover_enabled=”off” button_one_border_color__hover_enabled=”off” button_two_border_color__hover_enabled=”off” button_border_radius__hover_enabled=”off” button_one_border_radius__hover_enabled=”off” button_two_border_radius__hover_enabled=”off” button_letter_spacing__hover_enabled=”off” button_one_letter_spacing__hover_enabled=”off” button_two_letter_spacing__hover_enabled=”off” button_bg_color__hover_enabled=”off” button_one_bg_color__hover_enabled=”off” button_two_bg_color__hover_enabled=”off”][\/et_pb_contact_field][et_pb_contact_field field_id=”Email” field_title=”Adresa de e-mail” field_type=”email” _builder_version=”4.16″ global_colors_info=”{}” button_text_size__hover_enabled=”off” button_one_text_size__hover_enabled=”off” button_two_text_size__hover_enabled=”off” button_text_color__hover_enabled=”off” button_one_text_color__hover_enabled=”off” button_two_text_color__hover_enabled=”off” button_border_width__hover_enabled=”off” button_one_border_width__hover_enabled=”off” button_two_border_width__hover_enabled=”off” button_border_color__hover_enabled=”off” button_one_border_color__hover_enabled=”off” button_two_border_color__hover_enabled=”off” button_border_radius__hover_enabled=”off” button_one_border_radius__hover_enabled=”off” button_two_border_radius__hover_enabled=”off” button_letter_spacing__hover_enabled=”off” button_one_letter_spacing__hover_enabled=”off” button_two_letter_spacing__hover_enabled=”off” button_bg_color__hover_enabled=”off” button_one_bg_color__hover_enabled=”off” button_two_bg_color__hover_enabled=”off”][\/et_pb_contact_field][et_pb_contact_field field_id=”Message” field_title=”Mesajul dvs.” field_type=”text” fullwidth_field=”on” _builder_version=”4.16″ global_colors_info=”{}” button_text_size__hover_enabled=”off” button_one_text_size__hover_enabled=”off” button_two_text_size__hover_enabled=”off” button_text_color__hover_enabled=”off” button_one_text_color__hover_enabled=”off” button_two_text_color__hover_enabled=”off” button_border_width__hover_enabled=”off” button_one_border_width__hover_enabled=”off” button_two_border_width__hover_enabled=”off” button_border_color__hover_enabled=”off” button_one_border_color__hover_enabled=”off” button_two_border_color__hover_enabled=”off” button_border_radius__hover_enabled=”off” button_one_border_radius__hover_enabled=”off” button_two_border_radius__hover_enabled=”off” button_letter_spacing__hover_enabled=”off” button_one_letter_spacing__hover_enabled=”off” button_two_letter_spacing__hover_enabled=”off” button_bg_color__hover_enabled=”off” button_one_bg_color__hover_enabled=”off” button_two_bg_color__hover_enabled=”off”][\/et_pb_contact_field][\/et_pb_contact_form][\/et_pb_column][et_pb_column type=”2_5″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.19.4″ text_font=”Kaushan Script||||||||” text_text_color=”#f0622a” text_font_size=”30px” header_font=”||||||||” background_layout=”dark” global_colors_info=”{}”]<\/p>\n
Operatorul PDI 2023<\/p>\n
[\/et_pb_text][et_pb_text _builder_version=”4.16″ text_font=”||||||||” global_colors_info=”{}”]<\/p>\n
![\"\"](\"https:\/\/pdi.ro\/2023\/2022\/wp-content\/uploads\/2020\/02\/eventer_logo_150px.png\")
<\/span><\/p>\n<\/span><\/p>\n<\/span><\/p>\nAdresa: Str. A. Panu nr. 13, Iasi<\/span>
Tel.: 0332.40.88.00-05<\/span>
E-mail: contact@pdi.ro<\/a>
<\/span>Website:\u00a0<\/span>www.eventernet.ro<\/a><\/p>\n[\/et_pb_text][et_pb_text disabled_on=”off|off|off” _builder_version=”4.20.2″ text_font=”Kaushan Script||||||||” text_text_color=”#f0622a” text_font_size=”30px” header_font=”||||||||” background_layout=”dark” locked=”off” global_colors_info=”{}”]<\/p>\n
Parteneri Media<\/p>\n
[\/et_pb_text][et_pb_slider disabled_on=”off|off|off” _builder_version=”4.20.4″ _module_preset=”default” position_origin_r=”bottom_left” width=”200px” max_width=”200px” content_width=”200px” content_max_width=”200px” min_height=”100px” height=”100px” max_height=”100px” custom_margin=”0px||0px||false|false” custom_padding=”0px||0px||false|false” auto=”on” auto_speed=”3000″ global_colors_info=”{}”][et_pb_slide _builder_version=”4.20.2″ _module_preset=”default” background_enable_color=”off” background_image=”https:\/\/pdi.ro\/2023\/2022\/wp-content\/uploads\/2022\/05\/timpul_.jpg” background_enable_image=”on” background_size=”initial” custom_padding=”0px||0px||false|false” link_option_url=”#” link_option_url_new_window=”on” global_colors_info=”{}” sticky_transition=”on”][\/et_pb_slide][et_pb_slide _builder_version=”4.20.2″ _module_preset=”default” background_enable_color=”off” background_image=”https:\/\/pdi.ro\/2023\/2022\/wp-content\/uploads\/2022\/05\/medical-market_.jpg” background_enable_image=”on” background_size=”initial” custom_padding=”0px||0px||false|false” link_option_url=”https:\/\/issuu.com\/finwatch\/docs\/dermato?fr=sYWIzMjQ1MDUxNTY” link_option_url_new_window=”on” global_colors_info=”{}” sticky_transition=”on”][\/et_pb_slide][et_pb_slide button_text=”Click Here” _builder_version=”4.20.4″ _module_preset=”default” background_color=”RGBA(255,255,255,0)” background_enable_color=”on” background_image=”https:\/\/pdi.ro\/2023\/wp-content\/uploads\/2023\/04\/Logo-JURMED-RGB.jpg” background_enable_image=”on” background_size=”contain” link_option_url=”https:\/\/jurmed.ro\/” link_option_url_new_window=”on” global_colors_info=”{}” sticky_transition=”on”][\/et_pb_slide][\/et_pb_slider][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"
Prof. Dr. Daciana Elena Br\u0103ni\u0219teanuUniversitatea de Medicin\u0103 \u0219i Farmacie \u201cGrigore T. Popa\u201d Ia\u0219iSpitalul Clinic Universitar CF Ia\u0219iSimpozion SANDOZ Inova\u021bie continu\u0103 \u00een managementul onicomicozei Simpozion ACM Heliocare: foto-imunoprotec\u021bie dermatologic\u0103 3600 oral\u0103 \u0219i topic\u0103 Simpozion URIAGE Pruriced cu patentul PAR-2 REGUL, inova\u021bia Uriage \u00eempotriva pruritului Daciana Elena Br\u0103ni\u0219teanu Universitatea de Medicin\u0103 \u0219i Farmacie \u201cGrigore T. Popa\u201d Ia\u0219i, […]<\/p>\n","protected":false},"author":2,"featured_media":11595,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[12],"tags":[],"class_list":["post-11586","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-lectori"],"_links":{"self":[{"href":"https:\/\/pdi.ro\/2023\/wp-json\/wp\/v2\/posts\/11586","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pdi.ro\/2023\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pdi.ro\/2023\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pdi.ro\/2023\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/pdi.ro\/2023\/wp-json\/wp\/v2\/comments?post=11586"}],"version-history":[{"count":15,"href":"https:\/\/pdi.ro\/2023\/wp-json\/wp\/v2\/posts\/11586\/revisions"}],"predecessor-version":[{"id":13148,"href":"https:\/\/pdi.ro\/2023\/wp-json\/wp\/v2\/posts\/11586\/revisions\/13148"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pdi.ro\/2023\/wp-json\/wp\/v2\/media\/11595"}],"wp:attachment":[{"href":"https:\/\/pdi.ro\/2023\/wp-json\/wp\/v2\/media?parent=11586"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pdi.ro\/2023\/wp-json\/wp\/v2\/categories?post=11586"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pdi.ro\/2023\/wp-json\/wp\/v2\/tags?post=11586"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
Prof. Dr. Daciana Elena Br\u0103ni\u0219teanu<\/strong><\/span>
Universitatea de Medicin\u0103 \u0219i Farmacie \u201cGrigore T. Popa\u201d Ia\u0219i
Spitalul Clinic Universitar CF Ia\u0219i<\/strong><\/span><\/h4>\n[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”4.16″ locked=”off” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.20.4″ hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]<\/p>\n
Simpozion SANDOZ<\/span>
\nInova\u021bie continu\u0103 \u00een managementul onicomicozei<\/span><\/p>\nSimpozion ACM<\/span>
\nHeliocare: foto-imunoprotec\u021bie dermatologic\u0103 3600 oral\u0103 \u0219i topic\u0103<\/span><\/p>\nSimpozion URIAGE<\/span>
\nPruriced cu patentul PAR-2 REGUL, inova\u021bia Uriage \u00eempotriva pruritului<\/span>
\nDaciana Elena Br\u0103ni\u0219teanu
\nUniversitatea de Medicin\u0103 \u0219i Farmacie \u201cGrigore T. Popa\u201d Ia\u0219i, Rom\u00e2nia
\nSpitalul Clinic Universitar CF Ia\u0219i, Rom\u00e2nia<\/p>\nCuvinte cheie: prurit, boli de piele, afec\u021biuni sistemice, hemato-oncologie, oncologie<\/p>\n
Pruritul este cel mai frecvent simptom \u00een dermatologie \u0219i se reg\u0103se\u0219te, de asemenea, \u0219i \u00een alte patologii din medicina intern\u0103, endocrinologie, hepatologie, oncologie etc.
\nAcest simptom are cauze fiziologice sau patologice, intensitate de la discret\u0103 la sever\u0103, durat\u0103 de la ocazional\u0103 la cronic\u0103 \u0219i poate afecta corpul localizat sau generalizat.
\nDeoarece este manifestat \u00eentr-o multitudine de afec\u021biuni, afect\u00e2nd calitatea vie\u021bii pacien\u021bilor, este bine de \u0219tiut c\u0103 exist\u0103 produse dermato-cosmetice care pot fi recomandate pentru a reduce pruritul, de sine st\u0103t\u0103tor sau \u00een asociere cu alte tratamente.
\nURIAGE a dezvoltat gama Pruriced, cu patentul inovator PAR-2 Regul, Calamin\u0103, Ap\u0103 Termal\u0103 Uriage \u0219i p\u00e2n\u0103 la 96% ingrediente de origine natural\u0103.
\nPatentul PAR-2 Regul moduleaz\u0103 receptorul PAR2 care se implicat \u00een ambele c\u0103i ale pruritului \u2013 histaminic\u0103 \u0219i non-histaminic\u0103. Astfel, reduce expresia substan\u021belor pruriginoase \u0219i reduce pruritul.
\nCalamina este cunoscut\u0103 pentru propriet\u0103\u021bile sale calmante, hidratante, antipruriginoase, purificatoare \u0219i revigorante.
\nApa Termal\u0103 Uriage este o ap\u0103 izotonic\u0103, filmogenic\u0103, bogat\u0103 \u00een minerale \u0219i oligoelemente, activ\u0103 \u0219i cu propriet\u0103\u021bi unice de hidratare, calmare, vindecare \u0219i refacere a barierei cutanate.
\nPruriced este disponibil \u00een 3 formate de produs, potrivit pentru recomandare \u00een diferite tipuri de patologii sau nevoi de \u00eengrijire:
\n\u2022 Pruriced Crem\u0103 Calmant\u0103 \u2013 pentru prurit localizat sau generalizat, pe piele f\u0103r\u0103 p\u0103r, precum \u0219i prurit \u00een condi\u021bii diverse asociat pielii uscate.
\n\u2022 Pruriced Gel Calmant \u2013 pentru prurit generalizat sau localizat, \u00een zone cu p\u0103r, pliuri, zone extinse \u0219i zone intime externe.
\n\u2022 Pruriced SOS dup\u0103 \u00een\u021bep\u0103turi de insecte.
\nToate produsele pot fi recomandate de la nou n\u0103scu\u021bi p\u00e2n\u0103 la pacien\u021bii v\u00e2rstnici, \u00een func\u021bie de patologie.<\/p>\n
Pruriced, with PAR-2 Regul patent, Uriage innovation against pruritus\/itching<\/span><\/p>\nDaciana Elena Br\u0103ni\u0219teanu
\nUniversity of Medicine and Pharmacy “Grigore T. Popa” Iasi, Romania
\nCF Iasi University Clinical Hospital, Romania<\/p>\n
Keywords: pruritus, skin diseases, systemic diseases, hemato-oncology, oncology<\/p>\n
Itching is the most common symptom in dermatology and is also found in other pathologies in internal medicine, endocrinology, hepatology, oncology, etc.
\nThis symptom has physiological or pathological causes, variable intensity from discrete to severe, variable duration from occasional to chronic, and can affect the body locally or entirely.
\nIt is present in a multitude of conditions, affecting patients\u2019 quality of life. This is why it is important to know that there are dermato-cosmetic products that can be recommended to reduce pruritus, alone or associated with other treatments.
\nURIAGE has developed the Pruriced range, with the innovative PAR-2 Regul patent, Calamine, Uriage Thermal Water and up to 96% ingredients of natural origin.
\nPAR-2 Regul patent modulates the PAR2 receptor involved in the 2 pathways of pruritus \u2013 histaminic and non-histaminic. Thus, it reduces the expression of pruritic substances and reduces itching.
\nCalamine is known for its soothing, moisturizing, antipruritic, purifying and invigorating properties.
\nUriage Thermal Water is an isotonic, filmogenic water, rich in minerals and trace elements, active and with unique properties of hydrating, calming, healing and restoring the skin barrier.
\nPruriced is available in 3 product formats, suitable for recommendation in different types of pathologies or care needs:
\n\u2022 Pruriced Soothing Cream \u2013 for localized or generalized itching, on skin without hair, as well as itching in various conditions associated with dry skin.
\n\u2022 Pruriced Soothing Gel \u2013 for generalized or localized itching, in areas with hair, folds, extended areas and external intimate areas.
\n\u2022 Pruriced SOS after insect bites.
\nAll products can be recommended to patients of different ages, from newborns to elderly ones, depending on the pathology.<\/p>\n
Simpozion SERVIER<\/span>
\nBoala Venoasa Cronic\u0103: dincolo de semne…<\/span><\/p>\nDaciana Elena Br\u0103ni\u0219teanu
\nUniversitatea de Medicin\u0103 \u0219i Farmacie \u201cGrigore T. Popa\u201d Ia\u0219i, Rom\u00e2nia
\n\u015eef al Clinicii de Dermatologie, Spitalul Clinic CF Ia\u0219i, Rom\u00e2nia<\/p>\n
Cuvinte cheie: boala venoas\u0103 cronic\u0103, riscuri, medicamentul venoactiv de referin\u021b\u0103<\/p>\n
Este binecunoscut faptul c\u0103 Boala Venoas\u0103 Cronic\u0103 este o boal\u0103 progresiv\u0103 cu o prevalen\u021b\u0103 crescut\u0103 \u00een r\u00e2ndul popula\u021biei adulte. \u0218tim \u0219i pentru c\u0103, dincolo de datelele epidemiologice, diagnostic\u0103m un num\u0103r mare de pacien\u021bi \u00een practica medical\u0103 zilnic\u0103\u2026iar ceea ce putem observa sunt at\u00e2t semnele caracteristice bolii, c\u00e2t \u0219i afectarea calit\u0103\u021bii vie\u021bii pacien\u021bilor. Este important \u0219i s\u0103 afl\u0103m dac\u0103 dincolo de ceea ce este vizibil, sunt \u0219i riscuri la care pacien\u021bii cu Boal\u0103 Venoas\u0103 Cronic\u0103 sunt expu\u0219i. V\u0103 invit\u0103m s\u0103 participa\u021bi la eveniment pentru a descoperi toate acestea, dar \u0219i cum putem interveni eficient terapeutic!<\/p>\n
Chronic venous disease: beyond signs\u2026<\/span><\/p>\nDaciana Elena Br\u0103ni\u0219teanu
\nThe University of Medicine and Pharmacy \u201cGrigore T. Popa\u201d Iasi, Romania
\nHead of the Dermatology Clinic, CF Clinical Hospital Iasi, Romania<\/p>\n
Keywords: chronic venous disease, risks, the reference venoactive drug<\/p>\n
It is well known that Chronic Venous Disease is a progressive disease with an increased prevalence among the adult population. We also know because, beyond the epidemiological data, we diagnose a large number of patients in our daily medical practice…and what we can observe are both the characteristic signs of the disease and the impact on the patients’ quality of life. It is also important to find out if, beyond what is visible, there are also risks to which patients with Chronic Venous Disease are exposed. We invite you to take part in this event to discover all these, but also how we can effectively intervene therapeutically!<\/p>\n
SESIUNE \u015eTIIN\u0162IFIC\u0102 ORGANIZAT\u0102 CU SUS\u0162INEREA COMPANIEI TERAPIA<\/span>
\nLocul Ilumetri \u00een abordarea personalizat\u0103 a pacientului cu psoriazis<\/span><\/p>\nSESIUNE \u015eTIIN\u0162IFIC\u0102 ORGANIZAT\u0102 CU SUS\u0162INEREA COMPANIEI SANOFI<\/span>
\nDupixent \u2013 2 ani de success terapeutic \u00een Rom\u00e2nia<\/span><\/p>\nSESIUNE \u015eTIIN\u0162IFIC\u0102 ORGANIZAT\u0102 CU SUS\u0162INEREA COMPANIEI JANSSEN<\/span>
\nDiferen\u021bierile moleculare ale inhibitorilor IL-23 influen\u021beaz\u0103 r\u0103spunsul \u00een tratamentul psoriazisului<\/span><\/p>\nSimpozion NOVARTIS<\/span>
\nCOSENTYX \u2013 tratamentul complet al bolii psoriazice<\/span><\/p>\nSimpozion LILLY<\/span>
\nO nou\u0103 abordare terapeutic\u0103 oral\u0103 \u00een dermatita atopic\u0103 \u2013 inhibitorul Jak Olumiant<\/span><\/p>\nCodrina Ancu\u021ba1, Daciana Br\u0103ni\u0219teanu2, A. Nicolescu3
\n1U.M.F. \u201dGrigore T. Popa\u201d Reumatologie Ia\u0219i, Rom\u00e2nia
\n2U.M.F. \u201dGrigore T. Popa\u201d Dermatologie Ia\u0219i, Rom\u00e2nia
\n3Dermatologie Bucure\u0219ti, Rom\u00e2nia<\/p>\n
Cuvinte cheie: dermatit\u0103 atopic\u0103, imunomodula\u021bie, JAK(i), terapie oral\u0103, protocol terapeutic<\/p>\n
Misiunea noastr\u0103 \u00een imunologie este aceea de a \u00eembun\u0103t\u0103\u021bi via\u021ba pacien\u021bilor \u0219i consider\u0103m c\u0103 medicamentele noastre pot redefini op\u021biunile terapeutice \u00een psoriazis, dermatita atopic\u0103, artrita psoriazic\u0103, artrita reumatoid\u0103, spondiloartritele axiale, bolile inflamatorii intestinale, acest lucru \u00eensemn\u00e2nd ridicarea continu\u0103 a \u0219tachetei \u00een acest domeniu. Dermatita atopic\u0103 este una dintre cele mai frecvente afec\u021biuni cutanate, \u00eent\u00e2lnit\u0103 la p\u00e2n\u0103 la 20% dintre copii \u0219i la 2 \u2013 10% dintre adul\u021bi \u0219i are un caracter cronic, cu o evolu\u021bie recidivant\u0103. Tratamentul \u00een dermatita atopic\u0103 trebuie adaptat gradului de severitate, obiectivele principale fiind suprimarea inflama\u021biei \u0219i restabilirea func\u021biei de barier\u0103 \u0219i pielii. Este important de re\u021binut c\u0103 dermatita atopic\u0103 sever\u0103 poate fi tratat\u0103 cu medica\u021bie sistemic\u0103, conven\u021bional\u0103, biologic\u0103 sau sintetic\u0103-\u021bintit\u0103. Dintre moleculele sintetice-\u021bintite face parte \u0219i baricitinib, un inhibitor intra-celular al c\u0103ii JAK-STAT, cu o experien\u021b\u0103 semnificativ\u0103 \u00een reumatologie, \u00een indica\u021bia artrit\u0103 reumatoid\u0103, care \u00eencep\u00e2nd din anul 2020 este indicat \u0219i \u00een dermatita atopic\u0103 moderat\u0103 p\u00e2n\u0103 la sever\u0103 la pacien\u021bi adul\u021bi candida\u021bi pentru terapie sistemic\u0103.<\/p>\n
A New Approach of the Oral Treatment in Atopic Dermatitis \u2013 Olumiant, the JAK-inhibitor<\/span><\/p>\nCodrina Ancu\u021ba1, Daciana Br\u0103ni\u0219teanu2, A. Nicolescu3
\n1Rheumatology U.M.F. \u201dGrigore T. Popa\u201d Iasi, Romania
\n2Dermatology U.M.F. \u201dGrigore T. Popa\u201d Iasi, Romania
\n3Dermatology Bucharest, Romania<\/p>\n
Keywords: atopic dermatitis, immunomodulatory, JAK(i), oral therapy, therapeutic protocol<\/p>\n
Our mission in immunology is to improve the lives of patients and we believe that our drugs can redefine the therapeutic options in psoriasis, atopic dermatitis, psoriatic arthritis, rheumatoid arthritis, axial spondylarthritis, inflammatory bowel disease, which means continuously raising the bar.
\nAtopic dermatitis is one of the most common skin conditions, found in up to 20% of children and 2-10% of adults and has a chronic course, with a recurrent evolution. The treatment in atopic dermatitis must be adapted to the degree of severity, the main objectives being the suppression of inflammation and the restoration of the skin barrier function. It is important to note that severe atopic dermatitis can be treated with systemic, conventional, biological, or synthetic-targeted medication. Among the synthetic-targeted molecules is baricitinib, an intracellular inhibitor of the JAK-STAT pathway, with significant experience in rheumatology, in the indication of rheumatoid arthritis, which since 2020 is also indicated in moderate to severe atopic dermatitis in adult patients who are candidates for systemic therapy.<\/p>\n
Simpozion ABBVIE<\/span>
\nSkyrizi – viitorul \u00een psoriazis este acum!<\/span><\/p>\nDaciana Br\u0103ni\u0219teanu1, Carmen Curea2
\n1Sec\u021bia de Dermatovenerologie, Spitalul Clinic CF Ia\u0219i, Rom\u00e2nia
\n2Spitalul Clinic Colentina, Bucure\u0219ti, Rom\u00e2nia<\/p>\n
Psoriazisul este o boal\u0103 inflamatorie frecvent\u0103, cu comorbidit\u0103\u021bi semnificative, al c\u0103rei management poate fi dificil, av\u00e2nd \u00een vedere varietatea op\u021biunilor de tratament. Este esen\u021bial ca medicii s\u0103 aib\u0103 informa\u021bii utile despre tratamentul \u0219i monitorizarea pacien\u021bilor cu boal\u0103 psoriazic\u0103. De\u0219i anumite aspecte ale \u00eengrijirii se aplic\u0103 tuturor pacien\u021bilor, fiecare agent terapeutic are propriul s\u0103u profil cu impact direct \u00een ceea ce prive\u0219te evaluarea pacien\u021bilor, schema de administrare \u0219i monitorizarea. Alegerea tratamentului se bazeaz\u0103 nu numai pe severitatea bolii ci \u0219i pe comorbidit\u0103\u021bile \u0219i terapiile concomitente. Compania AbbVie va prezenta o solu\u021bie terapeutic\u0103 pentru managementul bolii psoriazice cu dovezi din studii clinice \u0219i date din via\u021ba real\u0103. Va fi detaliat mecanismul de ac\u021biune \u0219i cum influen\u021beaz\u0103 acesta rezultatele de eficacitate, durabilitate, siguran\u021b\u0103 \u0219i simplitate \u00een administrare.
\nDe asemenea se vor detalia date pe termen scurt \u0219i pe termen lung care ofer\u0103 o imagine a terapiilor avansate utilizate \u00een practica clinic\u0103 \u00een ceea ce prive\u0219te eficacitatea \u0219i tolerabilitatea.
\nNu \u00een ultimul r\u00e2nd, \u00een simpozionul Abbvie se vor eviden\u021bia aspecte practice legate de managementul terapeutic modern al pacien\u021bilor cu psoriazis moderat \u0219i sever.<\/p>\n
The Future in Psoriasis is Now!<\/span><\/p>\nDaciana Br\u0103ni\u0219teanu1, Carmen Curea2
\n1Department of Dermatovenerology, CF Iasi Clinical Hospital, Romania
\n2 Colentina Clinical Hospital, Bucharest, Romania<\/p>\n
Psoriasis is a common inflammatory disease with significant comorbidities, the management of which can be difficult given the variety of treatment options. It is essential for the physicians to have useful information about the treatment and monitoring of patients with psoriatic disease. Although certain aspects of care apply to all patients, each therapeutic agent has its own profile with direct impact on patient assessment, dosing schedule and monitoring. The choice of treatment is based not only on the severity of the disease but also on comorbidities and concomitant therapies. AbbVie will present a therapeutic solution for the management of psoriatic disease with clinical trial evidence and real-life data. The mechanism of action will be detailed and how it influences the results of effectiveness, durability, safety and simplicity in administration.
\nShort-term and long-term data that provide a picture of advanced therapies used in clinical practice in terms of efficacy and tolerability will be presented also.
\nLast but not least, the Abbvie symposium will highlight practical aspects related to the modern therapeutic management of patients with moderate and severe psoriasis.<\/p>\n
Simpozion ANTIBIOTICE<\/span>
\nBeneficiile de la A la Z pentru pacien\u021bii cu rozacee. Expertiza industriei farmaceutice rom\u00e2ne\u0219ti<\/span><\/p>\nDaciana Br\u0103ni\u015fteanu
\nU.M.F. \u201cGrigore T. Popa\u201d Ia\u015fi, Rom\u00e2nia<\/p>\n
Cuvinte cheie: rozacee, dermatocosmetice, acid azelaic<\/p>\n
Cu o expertiz\u0103 de peste 65 de ani \u00een formularea medicamentelor dermatologice, compania Antibiotice a inaugurat \u00een 2022 cea mai modern\u0103 fabric\u0103 de produse topice din Europa. \u00cen mod firesc, portofoliului de produse i s-a al\u0103turat \u00een 2023, o nou\u0103 linie de dermatocosmetice, Tinero\u00ae AZ, destinat\u0103 \u00eengrijirii de la A la Z a tenului cu rozacee.
\nUn aspect important \u00een strategia terapeutic\u0103 destinat\u0103 rozaceei \u00eel constituie asocierea produselor dermatocosmetice. Linia Tinero\u00ae AZ are un rol important \u00een managementul rozaceei, prin controlul seboreei, refacerea func\u0163iei de barier\u0103 epidermic\u0103, sc\u0103derea inflama\u0163iei \u0219i reducerea eritemului.
\nLinia Tinero\u00ae AZ con\u0163ine trei produse (spum\u0103 pentru cur\u0103\u0163area bl\u00e2nd\u0103 a tenului, ser, crem\u0103 cu factor de protec\u0163ie solar\u0103) pe baz\u0103 de acid azelaic, un constituent natural al tegumentului. Acesta are un rol important \u00een tratamentul rozaceei, \u00een principal prin ac\u0163iunea antiinflamatorie \u0219i antioxidant\u0103. Date din literatur\u0103 \u00eei atribuie \u0219i o ac\u0163iune \u00eempotriva bacilului Oleronius.
\nGhidul de diagnostic \u0219i tratament al rozaceei, elaborat de SRD \u00een 2022, stipuleaz\u0103 c\u0103 \u00een func\u0163ie de gradul de seboree sau de iritare al fe\u0163ei, putem recomanda produse
\ndermatocosmetice sub form\u0103 de spum\u0103 (pentru ten cu grad redus de seboree) \u0219i produse pentru aplica\u0163ii \u00een timpul zilei, care con\u0163in ingrediente cu rol fotoprotector. \u00cen ceea ce prive\u015fte compozi\u0163ia, ghidul recomand\u0103 ingrediente cu ac\u0163iune antiiritant\u0103 \u0219i antiinflamatorie precum glicirizatul dipotasic \u0219i ceramidele, \u00eent\u00e2lnite de asemenea \u00een produsele din linia Tinero\u00ae AZ.<\/p>\n
Benefits from A to Z for rosacea patients. Romanian pharmaceutical industry expertise<\/span><\/p>\nDaciana Br\u0103ni\u015fteanu
\nU.M.F. \u201cGrigore T. Popa\u201d Iasi, Romania<\/p>\n
Keywords: rosacea, cosmeceuticals, azelaic acid<\/p>\n
With an expertise of over 65 years in dermatological medicines formulation, Antibiotice opened in 2022 the most modern factory of topical products in Europe. Subsequently, the product portfolio welcomed in 2023 a new line of cosmeceuticals, Tinero\u00ae AZ, for the management of rosacea, from A to Z.
\nAn important aspect in rosacea therapeutic strategy is adding cosmeceuticals in therapeutical algorithm. Tinero\u00ae AZ line has an important role in the management of rosacea, by controlling seborrhea, restoring the epidermal barrier function, reducing inflammation and reducing erythema.
\nTinero\u00ae AZ line contains three products (foam for skin\u2019s gentle cleansing, serum and SPF hydrating cream) based on azelaic acid, a natural constituent of the skin. It has an important role in the treatment of rosacea, mainly through its anti-inflammatory and antioxidant action. It is also cited in literature azelaic acid\u2019s action against the Oleronius bacillus.
\nThe rosacea diagnosis and treatment guide, developed by the Romanian Dermatology Society in 2022, stipulates that depending on the degree of seborrhea or facial irritation, we can recommend cosmeceuticals like foam (for a low degree of seborrhea skin) and products for daytime applications, which contain ingredients with a photoprotective role. Regarding the composition, the guide recommends as well ingredients with anti-irritant and anti-inflammatory action such as dipotassium glycyrrhizate and ceramides which are also found Tinero\u00ae AZ line.<\/p>\n
Simpozion UCB<\/span>
\nBimzelx transform\u0103 visul de PASI 100 \u00een realitate<\/span><\/p>\nSESIUNE \u015eTIIN\u0162IFIC\u0102 ORGANIZAT\u0102 CU SUS\u0162INEREA COMPANIEI JANSSEN<\/span>
\nA GUIDE to early intervention and disease modification in psoriasis<\/span><\/p>\nSESIUNE \u015eTIIN\u0162IFIC\u0102 ORGANIZAT\u0102 CU SUS\u0162INEREA COMPANIEI ABBVIE<\/span>
\nProvoc\u0103ri \u00een dermatologia clinic\u0103 – focus \u00een dermatita atopic\u0103 \u0219i psoriazis<\/span><\/p>\nSimpozion LILLY<\/span>
\nSesiune de discu\u021bii: dermatita atopic\u0103 la adult \u2013 diagnostic \u0219i tratament<\/span><\/p>\nModerator: Daciana Br\u0103ni\u0219teanu3
\nSpeakeri: Carmen Curea1, A. Nicolescu2
\n1Spitalul Colentina Dermatologie Bucure\u0219ti, Rom\u00e2nia
\n2Dermatologie Bucure\u0219ti, Rom\u00e2nia
\n3U.M.F. \u201dGrigore T. Popa\u201d Dermatologie Ia\u0219i, Rom\u00e2nia<\/p>\n
Cuvinte cheie: protocol terapeutic, dermatit\u0103 atopic\u0103 la adul\u021bi, terapie oral\u0103<\/p>\n
Dermatita atopic\u0103 este mai mult dec\u00e2t o boal\u0103 a pielii, av\u00e2nd o dubl\u0103 dimensiune \u2013 o latur\u0103 medical\u0103 \u0219i o latur\u0103 social\u0103 sau de integrare. Dermatita atopic\u0103 este caracterizat\u0103 \u00een primul r\u00e2nd printr-un prurit excesiv, ceea ce impacteaz\u0103 cov\u0103r\u0219itor calitatea vie\u021bii pacien\u021bilor. Dermatit\u0103 atopic\u0103 netratat\u0103 se poate asocia foarte frecvent cu boli grave, dar \u0219i cu afectarea calit\u0103\u021bii vie\u021bii pacien\u021bilor, apari\u021bia absenteismului, prezenteismului \u0219i tulbur\u0103ri anxios-depresive. Diagnosticarea corect\u0103, inclusiv \u00eencadrarea \u00een gradul de severitate potrivit poate conduce la instituirea tratamentului adecvat \u0219i la \u00eembun\u0103t\u0103\u021birea prognosticului evolutiv pe termen lung. Aceasta este cu at\u00e2t mai important\u0103 \u00een contextul noilor terapii, unde alegerea trebuie individualizat\u0103 fiec\u0103rui pacient. Ideal, aceast\u0103 alegere ar trebui s\u0103 se bazeze pe caracteristicile \u0219tiin\u021bifice ale tratamentelor \u0219i nevoile individuale \u0219i mai pu\u021bin pe considerente de acces. \u00cen acest sens, rolul protocolului terapeutic este esen\u021bial \u00een permiterea accesului la terapia inovatoare rambursat\u0103 \u0219i la minimizarea considerentelor de acces din decizia medical\u0103.<\/p>\n
Open Discussion: Atopic Dermatitis in Adult Patients \u2013 Diagnostic and Therapy<\/span><\/p>\nModerator: Daciana Br\u0103ni\u0219teanu3
\nCarmen Curea1, A. Nicolescu2
\n1Dermatology Colentina Hospital Bucharest, Romania
\n2Dermatology Bucharest, Romania
\n3Dermatology U.M.F. \u201dGrigore T. Popa\u201d Iasi, Romania<\/p>\n
Atopic Dermatitis is more than a skin disease, having a dual dimension \u2013 a medical one and a social integration issue, as well. Atopic Dermatitis is characterised by an intense pruritus that impacts patient quality of life. Untreated Atopic Dermatitis can associate with other severe diseases, and also with depreciated QoL; presenteeism, absenteeism and depressive disorders. Correct diagnostic and severity measurement can lead to correct treatment initiations and improved prognosis on the longer term. This is even more important in the context of novel therapies and personalised treatment decisions are needed. Ideally, this treatment decisions must rely more on scientific, medical treatment and patient characteristics and less on access schemes. Therefore, the role of the therapeutic protocol is essential for the access to innovative reimbursed medicines, with minimal impact on the pharmaco-economic side.<\/p>\n
Simpozion AVENE<\/span>
\nTriAsorb – a ultra broad spectrum filter covering UVB UVA & HEV blue light up to 450nm<\/span><\/p>\nScurt CV<\/span><\/p>\n\u2013 Profesor universitar, titular de curs de dermatologie, Facultatea de Medicin\u0103, U.M.F. \u201cGrigore T. Popa\u201d, Ia\u0219i
\n\u2013 Doctor \u00een \u0219tiin\u021be medicale, teza de doctorat \u00een ACNEEA VULGARA (2004)
\n\u2013 Manager al Centrului de Dermatologie, Venerologie \u0219i Dermatocosmetologie \u201cDermaLux\u201d, din 2004 p\u00e2n\u0103 \u00een prezent
\n\u2013 \u0218ef sec\u021bie la Clinica Dermatologic\u0103 a Spitalului Clinic C\u0103i Ferate Ia\u0219i
\n\u2013 Competen\u021be \u00een anatomie patologic\u0103 cutanat\u0103 (Lyon, Fran\u021ba) \u0219i \u00een dermatocosmetologie
\n\u2013 Cursuri de supraspecializare \u00een Fran\u021ba, Lyon, Universite Lyon 2 (AFSA), cursuri europene de dermatoscopie, boala venoas\u0103 cronic\u0103, psoriazis, anti-aging, injectare de filere, laserterapie etc.
\n\u2013 Preocup\u0103ri deosebite pentru psoriazis: coordonator al Proiectului Na\u021bional Educa\u021bional \u201cPatologia psoriazisului\u201d, particip\u0103ri \u00een calitate de expert la \u00eent\u00e2lniri interna\u021bionale pe teme de psoriazis (Viena, Atena, Geneva etc.), articole publicate \u00een reviste na\u021bionale \u0219i interna\u021bionale, comunic\u0103ri orale, conferin\u021be, grupuri de lucru \u0219i workshop-uri pe tema psoriazisului
\n\u2013 Pre\u0219edinte al Asocia\u021biei Dermatologilor din Moldova, Pre\u0219edinte al manifest\u0103rii na\u021bionale cu participare interna\u021bional\u0103 \u201cPrim\u0103vara Dermatologic\u0103 Ie\u0219ean\u0103\u201d;
\n\u2013 Membru \u00een Comitetul Director al Societ\u0103\u021bii Rom\u00e2ne de Dermatologie
\n\u2013 Membru \u00een Grupul Interna\u021bional \u201cMedical Reporter\u2019s Academy\u201d, pe probleme de flebologie
\n\u2013 Membru al: Academiei Europene de Dermatologie, Academiei Americane de Dermatologie, Societ\u0103\u021bii Franceze de Dermatologie, Societ\u0103\u021bii Franceze de Flebologie, Societ\u0103\u021bii Interna\u021bionale de Dermatologie, Societ\u0103\u021bii de Dermatologie Investigativ\u0103, Societ\u0103\u021bii Rom\u00e2ne de Dermatopediatrie, Societ\u0103\u021bii Rom\u00e2ne de Dermatoimunologie, Societ\u0103\u021bii de Medici \u0219i Naturali\u0219ti
\n\u2013 Coordonator a peste 100 de cursuri de educa\u021bie medical\u0103 continu\u0103 \u0219i de cursuri postuniversitare
\n\u2013 Peste 400 de conferin\u021be, prelegeri \u0219i comunic\u0103ri orale sus\u021binute la manifest\u0103ri \u0219tiin\u021bifice, mese rotunde, conferin\u021be \u0219i congrese din \u021bar\u0103, nu doar de dermatologie
\n\u2013 Lector invitat la Congrese Interna\u021bionale ale: Societ\u0103\u021bii Europene de Dermatologie \u0219i Venerologie (EADV), Societ\u0103\u021bii Franceze de Flebologie (SFP), Uniunii Interna\u021bionale de Flebologie (UIP)
\n\u2013 Expert \u00een Boala Venoas\u0103 Cronic\u0103, \u00een Maladii Transmisibile Sexual, expert dermatolog \u00een solu\u021bionarea unor cazuri medico-legale
\n\u2013 Decan de Serie desemnat de c\u0103tre studen\u021bi, ca semn de respect \u0219i de recunoa\u0219tere a calit\u0103\u021bii de dasc\u0103l
\n\u2013 Implicare activ\u0103 \u00een activitatea de cercetare \u0219tiin\u021bific\u0103 (granturi de cercetare \u0219tiin\u021bific\u0103, proiecte na\u021bionale \u0219i interna\u021bionale, studii clinice, consultant \u0219tiin\u021bific, membru \u00een numeroase advisory board-uri etc.)
\n\u2013 Peste 230 de lucr\u0103ri publicate \u00een \u021bar\u0103 \u0219i \u00een str\u0103in\u0103tate, autoare a 23 c\u0103r\u021bi \u0219i capitole de c\u0103r\u021bi de dermatologie
\n\u2013 Absolvent\u0103 a Facult\u0103\u021bii de Medicin\u0103, U.M.F. \u201cGrigore T. Popa\u201d, Ia\u0219i, promo\u021bia 1991<\/p>\n
[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.19.4″ background_color=”rgba(240,98,42,0.19)” background_image=”https:\/\/pdi.ro\/2023\/wp-content\/uploads\/2022\/12\/PDI2023_header__-scaled.jpg” background_blend=”multiply” custom_padding=”54px|0px|0|0px|false|false” top_divider_style=”waves2″ top_divider_color=”#ffffff” top_divider_height=”155px” top_divider_height_tablet=”” top_divider_height_phone=”97px” top_divider_height_last_edited=”on|desktop” bottom_divider_style=”waves2″ bottom_divider_color=”#F0622A” bottom_divider_flip=”vertical” bottom_divider_height_tablet=”” bottom_divider_height_phone=”59px” bottom_divider_height_last_edited=”on|desktop” global_module=”9177″ saved_tabs=”all” global_colors_info=”{}”][et_pb_row column_structure=”3_5,2_5″ _builder_version=”4.19.4″ custom_padding=”100px|0px|69px|0px|false|false” global_colors_info=”{}”][et_pb_column type=”3_5″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text disabled_on=”off|off|off” _builder_version=”4.20.2″ text_font=”Kaushan Script||||||||” text_text_color=”#f0622a” text_font_size=”30px” text_line_height=”1.2em” header_font=”||||||||” background_layout=”dark” text_font_size_tablet=”” text_font_size_phone=”” text_font_size_last_edited=”on|desktop” global_colors_info=”{}”]<\/p>\n
Contacteaz\u0103 operatorul PDI 2023<\/p>\n
[\/et_pb_text][et_pb_contact_form email=”contact@pdi.ro” submit_button_text=”Trimite mesajul” disabled_on=”off|off|off” _builder_version=”4.20.2″ _unique_id=”794aaef5-e005-432a-99fb-9ca53e06d67b” title_font=”||||||||” custom_button=”on” button_text_color=”#F0622A” global_colors_info=”{}”][et_pb_contact_field field_id=”Name” field_title=”Nume” _builder_version=”4.16″ global_colors_info=”{}” button_text_size__hover_enabled=”off” button_one_text_size__hover_enabled=”off” button_two_text_size__hover_enabled=”off” button_text_color__hover_enabled=”off” button_one_text_color__hover_enabled=”off” button_two_text_color__hover_enabled=”off” button_border_width__hover_enabled=”off” button_one_border_width__hover_enabled=”off” button_two_border_width__hover_enabled=”off” button_border_color__hover_enabled=”off” button_one_border_color__hover_enabled=”off” button_two_border_color__hover_enabled=”off” button_border_radius__hover_enabled=”off” button_one_border_radius__hover_enabled=”off” button_two_border_radius__hover_enabled=”off” button_letter_spacing__hover_enabled=”off” button_one_letter_spacing__hover_enabled=”off” button_two_letter_spacing__hover_enabled=”off” button_bg_color__hover_enabled=”off” button_one_bg_color__hover_enabled=”off” button_two_bg_color__hover_enabled=”off”][\/et_pb_contact_field][et_pb_contact_field field_id=”Email” field_title=”Adresa de e-mail” field_type=”email” _builder_version=”4.16″ global_colors_info=”{}” button_text_size__hover_enabled=”off” button_one_text_size__hover_enabled=”off” button_two_text_size__hover_enabled=”off” button_text_color__hover_enabled=”off” button_one_text_color__hover_enabled=”off” button_two_text_color__hover_enabled=”off” button_border_width__hover_enabled=”off” button_one_border_width__hover_enabled=”off” button_two_border_width__hover_enabled=”off” button_border_color__hover_enabled=”off” button_one_border_color__hover_enabled=”off” button_two_border_color__hover_enabled=”off” button_border_radius__hover_enabled=”off” button_one_border_radius__hover_enabled=”off” button_two_border_radius__hover_enabled=”off” button_letter_spacing__hover_enabled=”off” button_one_letter_spacing__hover_enabled=”off” button_two_letter_spacing__hover_enabled=”off” button_bg_color__hover_enabled=”off” button_one_bg_color__hover_enabled=”off” button_two_bg_color__hover_enabled=”off”][\/et_pb_contact_field][et_pb_contact_field field_id=”Message” field_title=”Mesajul dvs.” field_type=”text” fullwidth_field=”on” _builder_version=”4.16″ global_colors_info=”{}” button_text_size__hover_enabled=”off” button_one_text_size__hover_enabled=”off” button_two_text_size__hover_enabled=”off” button_text_color__hover_enabled=”off” button_one_text_color__hover_enabled=”off” button_two_text_color__hover_enabled=”off” button_border_width__hover_enabled=”off” button_one_border_width__hover_enabled=”off” button_two_border_width__hover_enabled=”off” button_border_color__hover_enabled=”off” button_one_border_color__hover_enabled=”off” button_two_border_color__hover_enabled=”off” button_border_radius__hover_enabled=”off” button_one_border_radius__hover_enabled=”off” button_two_border_radius__hover_enabled=”off” button_letter_spacing__hover_enabled=”off” button_one_letter_spacing__hover_enabled=”off” button_two_letter_spacing__hover_enabled=”off” button_bg_color__hover_enabled=”off” button_one_bg_color__hover_enabled=”off” button_two_bg_color__hover_enabled=”off”][\/et_pb_contact_field][\/et_pb_contact_form][\/et_pb_column][et_pb_column type=”2_5″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.19.4″ text_font=”Kaushan Script||||||||” text_text_color=”#f0622a” text_font_size=”30px” header_font=”||||||||” background_layout=”dark” global_colors_info=”{}”]<\/p>\n
Operatorul PDI 2023<\/p>\n
[\/et_pb_text][et_pb_text _builder_version=”4.16″ text_font=”||||||||” global_colors_info=”{}”]<\/p>\n
<\/span><\/p>\n<\/span><\/p>\n<\/span><\/p>\nAdresa: Str. A. Panu nr. 13, Iasi<\/span>
Tel.: 0332.40.88.00-05<\/span>
E-mail: contact@pdi.ro<\/a>
<\/span>Website:\u00a0<\/span>www.eventernet.ro<\/a><\/p>\n[\/et_pb_text][et_pb_text disabled_on=”off|off|off” _builder_version=”4.20.2″ text_font=”Kaushan Script||||||||” text_text_color=”#f0622a” text_font_size=”30px” header_font=”||||||||” background_layout=”dark” locked=”off” global_colors_info=”{}”]<\/p>\n
Parteneri Media<\/p>\n
[\/et_pb_text][et_pb_slider disabled_on=”off|off|off” _builder_version=”4.20.4″ _module_preset=”default” position_origin_r=”bottom_left” width=”200px” max_width=”200px” content_width=”200px” content_max_width=”200px” min_height=”100px” height=”100px” max_height=”100px” custom_margin=”0px||0px||false|false” custom_padding=”0px||0px||false|false” auto=”on” auto_speed=”3000″ global_colors_info=”{}”][et_pb_slide _builder_version=”4.20.2″ _module_preset=”default” background_enable_color=”off” background_image=”https:\/\/pdi.ro\/2023\/2022\/wp-content\/uploads\/2022\/05\/timpul_.jpg” background_enable_image=”on” background_size=”initial” custom_padding=”0px||0px||false|false” link_option_url=”#” link_option_url_new_window=”on” global_colors_info=”{}” sticky_transition=”on”][\/et_pb_slide][et_pb_slide _builder_version=”4.20.2″ _module_preset=”default” background_enable_color=”off” background_image=”https:\/\/pdi.ro\/2023\/2022\/wp-content\/uploads\/2022\/05\/medical-market_.jpg” background_enable_image=”on” background_size=”initial” custom_padding=”0px||0px||false|false” link_option_url=”https:\/\/issuu.com\/finwatch\/docs\/dermato?fr=sYWIzMjQ1MDUxNTY” link_option_url_new_window=”on” global_colors_info=”{}” sticky_transition=”on”][\/et_pb_slide][et_pb_slide button_text=”Click Here” _builder_version=”4.20.4″ _module_preset=”default” background_color=”RGBA(255,255,255,0)” background_enable_color=”on” background_image=”https:\/\/pdi.ro\/2023\/wp-content\/uploads\/2023\/04\/Logo-JURMED-RGB.jpg” background_enable_image=”on” background_size=”contain” link_option_url=”https:\/\/jurmed.ro\/” link_option_url_new_window=”on” global_colors_info=”{}” sticky_transition=”on”][\/et_pb_slide][\/et_pb_slider][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"
Prof. Dr. Daciana Elena Br\u0103ni\u0219teanuUniversitatea de Medicin\u0103 \u0219i Farmacie \u201cGrigore T. Popa\u201d Ia\u0219iSpitalul Clinic Universitar CF Ia\u0219iSimpozion SANDOZ Inova\u021bie continu\u0103 \u00een managementul onicomicozei Simpozion ACM Heliocare: foto-imunoprotec\u021bie dermatologic\u0103 3600 oral\u0103 \u0219i topic\u0103 Simpozion URIAGE Pruriced cu patentul PAR-2 REGUL, inova\u021bia Uriage \u00eempotriva pruritului Daciana Elena Br\u0103ni\u0219teanu Universitatea de Medicin\u0103 \u0219i Farmacie \u201cGrigore T. Popa\u201d Ia\u0219i, […]<\/p>\n","protected":false},"author":2,"featured_media":11595,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[12],"tags":[],"class_list":["post-11586","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-lectori"],"_links":{"self":[{"href":"https:\/\/pdi.ro\/2023\/wp-json\/wp\/v2\/posts\/11586","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pdi.ro\/2023\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pdi.ro\/2023\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pdi.ro\/2023\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/pdi.ro\/2023\/wp-json\/wp\/v2\/comments?post=11586"}],"version-history":[{"count":15,"href":"https:\/\/pdi.ro\/2023\/wp-json\/wp\/v2\/posts\/11586\/revisions"}],"predecessor-version":[{"id":13148,"href":"https:\/\/pdi.ro\/2023\/wp-json\/wp\/v2\/posts\/11586\/revisions\/13148"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pdi.ro\/2023\/wp-json\/wp\/v2\/media\/11595"}],"wp:attachment":[{"href":"https:\/\/pdi.ro\/2023\/wp-json\/wp\/v2\/media?parent=11586"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pdi.ro\/2023\/wp-json\/wp\/v2\/categories?post=11586"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pdi.ro\/2023\/wp-json\/wp\/v2\/tags?post=11586"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\nInova\u021bie continu\u0103 \u00een managementul onicomicozei<\/span><\/p>\n
Simpozion ACM<\/span> Simpozion URIAGE<\/span> Cuvinte cheie: prurit, boli de piele, afec\u021biuni sistemice, hemato-oncologie, oncologie<\/p>\n Pruritul este cel mai frecvent simptom \u00een dermatologie \u0219i se reg\u0103se\u0219te, de asemenea, \u0219i \u00een alte patologii din medicina intern\u0103, endocrinologie, hepatologie, oncologie etc. Pruriced, with PAR-2 Regul patent, Uriage innovation against pruritus\/itching<\/span><\/p>\n Daciana Elena Br\u0103ni\u0219teanu Keywords: pruritus, skin diseases, systemic diseases, hemato-oncology, oncology<\/p>\n Itching is the most common symptom in dermatology and is also found in other pathologies in internal medicine, endocrinology, hepatology, oncology, etc. Simpozion SERVIER<\/span> Daciana Elena Br\u0103ni\u0219teanu Cuvinte cheie: boala venoas\u0103 cronic\u0103, riscuri, medicamentul venoactiv de referin\u021b\u0103<\/p>\n Este binecunoscut faptul c\u0103 Boala Venoas\u0103 Cronic\u0103 este o boal\u0103 progresiv\u0103 cu o prevalen\u021b\u0103 crescut\u0103 \u00een r\u00e2ndul popula\u021biei adulte. \u0218tim \u0219i pentru c\u0103, dincolo de datelele epidemiologice, diagnostic\u0103m un num\u0103r mare de pacien\u021bi \u00een practica medical\u0103 zilnic\u0103\u2026iar ceea ce putem observa sunt at\u00e2t semnele caracteristice bolii, c\u00e2t \u0219i afectarea calit\u0103\u021bii vie\u021bii pacien\u021bilor. Este important \u0219i s\u0103 afl\u0103m dac\u0103 dincolo de ceea ce este vizibil, sunt \u0219i riscuri la care pacien\u021bii cu Boal\u0103 Venoas\u0103 Cronic\u0103 sunt expu\u0219i. V\u0103 invit\u0103m s\u0103 participa\u021bi la eveniment pentru a descoperi toate acestea, dar \u0219i cum putem interveni eficient terapeutic!<\/p>\n Chronic venous disease: beyond signs\u2026<\/span><\/p>\n Daciana Elena Br\u0103ni\u0219teanu Keywords: chronic venous disease, risks, the reference venoactive drug<\/p>\n It is well known that Chronic Venous Disease is a progressive disease with an increased prevalence among the adult population. We also know because, beyond the epidemiological data, we diagnose a large number of patients in our daily medical practice…and what we can observe are both the characteristic signs of the disease and the impact on the patients’ quality of life. It is also important to find out if, beyond what is visible, there are also risks to which patients with Chronic Venous Disease are exposed. We invite you to take part in this event to discover all these, but also how we can effectively intervene therapeutically!<\/p>\n SESIUNE \u015eTIIN\u0162IFIC\u0102 ORGANIZAT\u0102 CU SUS\u0162INEREA COMPANIEI TERAPIA<\/span> SESIUNE \u015eTIIN\u0162IFIC\u0102 ORGANIZAT\u0102 CU SUS\u0162INEREA COMPANIEI SANOFI<\/span> SESIUNE \u015eTIIN\u0162IFIC\u0102 ORGANIZAT\u0102 CU SUS\u0162INEREA COMPANIEI JANSSEN<\/span> Simpozion NOVARTIS<\/span> Simpozion LILLY<\/span> Codrina Ancu\u021ba1, Daciana Br\u0103ni\u0219teanu2, A. Nicolescu3 Cuvinte cheie: dermatit\u0103 atopic\u0103, imunomodula\u021bie, JAK(i), terapie oral\u0103, protocol terapeutic<\/p>\n Misiunea noastr\u0103 \u00een imunologie este aceea de a \u00eembun\u0103t\u0103\u021bi via\u021ba pacien\u021bilor \u0219i consider\u0103m c\u0103 medicamentele noastre pot redefini op\u021biunile terapeutice \u00een psoriazis, dermatita atopic\u0103, artrita psoriazic\u0103, artrita reumatoid\u0103, spondiloartritele axiale, bolile inflamatorii intestinale, acest lucru \u00eensemn\u00e2nd ridicarea continu\u0103 a \u0219tachetei \u00een acest domeniu. Dermatita atopic\u0103 este una dintre cele mai frecvente afec\u021biuni cutanate, \u00eent\u00e2lnit\u0103 la p\u00e2n\u0103 la 20% dintre copii \u0219i la 2 \u2013 10% dintre adul\u021bi \u0219i are un caracter cronic, cu o evolu\u021bie recidivant\u0103. Tratamentul \u00een dermatita atopic\u0103 trebuie adaptat gradului de severitate, obiectivele principale fiind suprimarea inflama\u021biei \u0219i restabilirea func\u021biei de barier\u0103 \u0219i pielii. Este important de re\u021binut c\u0103 dermatita atopic\u0103 sever\u0103 poate fi tratat\u0103 cu medica\u021bie sistemic\u0103, conven\u021bional\u0103, biologic\u0103 sau sintetic\u0103-\u021bintit\u0103. Dintre moleculele sintetice-\u021bintite face parte \u0219i baricitinib, un inhibitor intra-celular al c\u0103ii JAK-STAT, cu o experien\u021b\u0103 semnificativ\u0103 \u00een reumatologie, \u00een indica\u021bia artrit\u0103 reumatoid\u0103, care \u00eencep\u00e2nd din anul 2020 este indicat \u0219i \u00een dermatita atopic\u0103 moderat\u0103 p\u00e2n\u0103 la sever\u0103 la pacien\u021bi adul\u021bi candida\u021bi pentru terapie sistemic\u0103.<\/p>\n A New Approach of the Oral Treatment in Atopic Dermatitis \u2013 Olumiant, the JAK-inhibitor<\/span><\/p>\n Codrina Ancu\u021ba1, Daciana Br\u0103ni\u0219teanu2, A. Nicolescu3 Keywords: atopic dermatitis, immunomodulatory, JAK(i), oral therapy, therapeutic protocol<\/p>\n Our mission in immunology is to improve the lives of patients and we believe that our drugs can redefine the therapeutic options in psoriasis, atopic dermatitis, psoriatic arthritis, rheumatoid arthritis, axial spondylarthritis, inflammatory bowel disease, which means continuously raising the bar. Simpozion ABBVIE<\/span> Daciana Br\u0103ni\u0219teanu1, Carmen Curea2 Psoriazisul este o boal\u0103 inflamatorie frecvent\u0103, cu comorbidit\u0103\u021bi semnificative, al c\u0103rei management poate fi dificil, av\u00e2nd \u00een vedere varietatea op\u021biunilor de tratament. Este esen\u021bial ca medicii s\u0103 aib\u0103 informa\u021bii utile despre tratamentul \u0219i monitorizarea pacien\u021bilor cu boal\u0103 psoriazic\u0103. De\u0219i anumite aspecte ale \u00eengrijirii se aplic\u0103 tuturor pacien\u021bilor, fiecare agent terapeutic are propriul s\u0103u profil cu impact direct \u00een ceea ce prive\u0219te evaluarea pacien\u021bilor, schema de administrare \u0219i monitorizarea. Alegerea tratamentului se bazeaz\u0103 nu numai pe severitatea bolii ci \u0219i pe comorbidit\u0103\u021bile \u0219i terapiile concomitente. Compania AbbVie va prezenta o solu\u021bie terapeutic\u0103 pentru managementul bolii psoriazice cu dovezi din studii clinice \u0219i date din via\u021ba real\u0103. Va fi detaliat mecanismul de ac\u021biune \u0219i cum influen\u021beaz\u0103 acesta rezultatele de eficacitate, durabilitate, siguran\u021b\u0103 \u0219i simplitate \u00een administrare. The Future in Psoriasis is Now!<\/span><\/p>\n Daciana Br\u0103ni\u0219teanu1, Carmen Curea2 Psoriasis is a common inflammatory disease with significant comorbidities, the management of which can be difficult given the variety of treatment options. It is essential for the physicians to have useful information about the treatment and monitoring of patients with psoriatic disease. Although certain aspects of care apply to all patients, each therapeutic agent has its own profile with direct impact on patient assessment, dosing schedule and monitoring. The choice of treatment is based not only on the severity of the disease but also on comorbidities and concomitant therapies. AbbVie will present a therapeutic solution for the management of psoriatic disease with clinical trial evidence and real-life data. The mechanism of action will be detailed and how it influences the results of effectiveness, durability, safety and simplicity in administration. Simpozion ANTIBIOTICE<\/span> Daciana Br\u0103ni\u015fteanu Cuvinte cheie: rozacee, dermatocosmetice, acid azelaic<\/p>\n Cu o expertiz\u0103 de peste 65 de ani \u00een formularea medicamentelor dermatologice, compania Antibiotice a inaugurat \u00een 2022 cea mai modern\u0103 fabric\u0103 de produse topice din Europa. \u00cen mod firesc, portofoliului de produse i s-a al\u0103turat \u00een 2023, o nou\u0103 linie de dermatocosmetice, Tinero\u00ae AZ, destinat\u0103 \u00eengrijirii de la A la Z a tenului cu rozacee. Benefits from A to Z for rosacea patients. Romanian pharmaceutical industry expertise<\/span><\/p>\n Daciana Br\u0103ni\u015fteanu Keywords: rosacea, cosmeceuticals, azelaic acid<\/p>\n With an expertise of over 65 years in dermatological medicines formulation, Antibiotice opened in 2022 the most modern factory of topical products in Europe. Subsequently, the product portfolio welcomed in 2023 a new line of cosmeceuticals, Tinero\u00ae AZ, for the management of rosacea, from A to Z. Simpozion UCB<\/span> SESIUNE \u015eTIIN\u0162IFIC\u0102 ORGANIZAT\u0102 CU SUS\u0162INEREA COMPANIEI JANSSEN<\/span> SESIUNE \u015eTIIN\u0162IFIC\u0102 ORGANIZAT\u0102 CU SUS\u0162INEREA COMPANIEI ABBVIE<\/span> Simpozion LILLY<\/span> Moderator: Daciana Br\u0103ni\u0219teanu3 Cuvinte cheie: protocol terapeutic, dermatit\u0103 atopic\u0103 la adul\u021bi, terapie oral\u0103<\/p>\n Dermatita atopic\u0103 este mai mult dec\u00e2t o boal\u0103 a pielii, av\u00e2nd o dubl\u0103 dimensiune \u2013 o latur\u0103 medical\u0103 \u0219i o latur\u0103 social\u0103 sau de integrare. Dermatita atopic\u0103 este caracterizat\u0103 \u00een primul r\u00e2nd printr-un prurit excesiv, ceea ce impacteaz\u0103 cov\u0103r\u0219itor calitatea vie\u021bii pacien\u021bilor. Dermatit\u0103 atopic\u0103 netratat\u0103 se poate asocia foarte frecvent cu boli grave, dar \u0219i cu afectarea calit\u0103\u021bii vie\u021bii pacien\u021bilor, apari\u021bia absenteismului, prezenteismului \u0219i tulbur\u0103ri anxios-depresive. Diagnosticarea corect\u0103, inclusiv \u00eencadrarea \u00een gradul de severitate potrivit poate conduce la instituirea tratamentului adecvat \u0219i la \u00eembun\u0103t\u0103\u021birea prognosticului evolutiv pe termen lung. Aceasta este cu at\u00e2t mai important\u0103 \u00een contextul noilor terapii, unde alegerea trebuie individualizat\u0103 fiec\u0103rui pacient. Ideal, aceast\u0103 alegere ar trebui s\u0103 se bazeze pe caracteristicile \u0219tiin\u021bifice ale tratamentelor \u0219i nevoile individuale \u0219i mai pu\u021bin pe considerente de acces. \u00cen acest sens, rolul protocolului terapeutic este esen\u021bial \u00een permiterea accesului la terapia inovatoare rambursat\u0103 \u0219i la minimizarea considerentelor de acces din decizia medical\u0103.<\/p>\n Open Discussion: Atopic Dermatitis in Adult Patients \u2013 Diagnostic and Therapy<\/span><\/p>\n Moderator: Daciana Br\u0103ni\u0219teanu3 Atopic Dermatitis is more than a skin disease, having a dual dimension \u2013 a medical one and a social integration issue, as well. Atopic Dermatitis is characterised by an intense pruritus that impacts patient quality of life. Untreated Atopic Dermatitis can associate with other severe diseases, and also with depreciated QoL; presenteeism, absenteeism and depressive disorders. Correct diagnostic and severity measurement can lead to correct treatment initiations and improved prognosis on the longer term. This is even more important in the context of novel therapies and personalised treatment decisions are needed. Ideally, this treatment decisions must rely more on scientific, medical treatment and patient characteristics and less on access schemes. Therefore, the role of the therapeutic protocol is essential for the access to innovative reimbursed medicines, with minimal impact on the pharmaco-economic side.<\/p>\n Simpozion AVENE<\/span> Scurt CV<\/span><\/p>\n \u2013 Profesor universitar, titular de curs de dermatologie, Facultatea de Medicin\u0103, U.M.F. \u201cGrigore T. Popa\u201d, Ia\u0219i [\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.19.4″ background_color=”rgba(240,98,42,0.19)” background_image=”https:\/\/pdi.ro\/2023\/wp-content\/uploads\/2022\/12\/PDI2023_header__-scaled.jpg” background_blend=”multiply” custom_padding=”54px|0px|0|0px|false|false” top_divider_style=”waves2″ top_divider_color=”#ffffff” top_divider_height=”155px” top_divider_height_tablet=”” top_divider_height_phone=”97px” top_divider_height_last_edited=”on|desktop” bottom_divider_style=”waves2″ bottom_divider_color=”#F0622A” bottom_divider_flip=”vertical” bottom_divider_height_tablet=”” bottom_divider_height_phone=”59px” bottom_divider_height_last_edited=”on|desktop” global_module=”9177″ saved_tabs=”all” global_colors_info=”{}”][et_pb_row column_structure=”3_5,2_5″ _builder_version=”4.19.4″ custom_padding=”100px|0px|69px|0px|false|false” global_colors_info=”{}”][et_pb_column type=”3_5″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text disabled_on=”off|off|off” _builder_version=”4.20.2″ text_font=”Kaushan Script||||||||” text_text_color=”#f0622a” text_font_size=”30px” text_line_height=”1.2em” header_font=”||||||||” background_layout=”dark” text_font_size_tablet=”” text_font_size_phone=”” text_font_size_last_edited=”on|desktop” global_colors_info=”{}”]<\/p>\n Contacteaz\u0103 operatorul PDI 2023<\/p>\n [\/et_pb_text][et_pb_contact_form email=”contact@pdi.ro” submit_button_text=”Trimite mesajul” disabled_on=”off|off|off” _builder_version=”4.20.2″ _unique_id=”794aaef5-e005-432a-99fb-9ca53e06d67b” title_font=”||||||||” custom_button=”on” button_text_color=”#F0622A” global_colors_info=”{}”][et_pb_contact_field field_id=”Name” field_title=”Nume” _builder_version=”4.16″ global_colors_info=”{}” button_text_size__hover_enabled=”off” button_one_text_size__hover_enabled=”off” button_two_text_size__hover_enabled=”off” button_text_color__hover_enabled=”off” button_one_text_color__hover_enabled=”off” button_two_text_color__hover_enabled=”off” button_border_width__hover_enabled=”off” button_one_border_width__hover_enabled=”off” button_two_border_width__hover_enabled=”off” button_border_color__hover_enabled=”off” button_one_border_color__hover_enabled=”off” button_two_border_color__hover_enabled=”off” button_border_radius__hover_enabled=”off” button_one_border_radius__hover_enabled=”off” button_two_border_radius__hover_enabled=”off” button_letter_spacing__hover_enabled=”off” button_one_letter_spacing__hover_enabled=”off” button_two_letter_spacing__hover_enabled=”off” button_bg_color__hover_enabled=”off” button_one_bg_color__hover_enabled=”off” button_two_bg_color__hover_enabled=”off”][\/et_pb_contact_field][et_pb_contact_field field_id=”Email” field_title=”Adresa de e-mail” field_type=”email” _builder_version=”4.16″ global_colors_info=”{}” button_text_size__hover_enabled=”off” button_one_text_size__hover_enabled=”off” button_two_text_size__hover_enabled=”off” button_text_color__hover_enabled=”off” button_one_text_color__hover_enabled=”off” button_two_text_color__hover_enabled=”off” button_border_width__hover_enabled=”off” button_one_border_width__hover_enabled=”off” button_two_border_width__hover_enabled=”off” button_border_color__hover_enabled=”off” button_one_border_color__hover_enabled=”off” button_two_border_color__hover_enabled=”off” button_border_radius__hover_enabled=”off” button_one_border_radius__hover_enabled=”off” button_two_border_radius__hover_enabled=”off” button_letter_spacing__hover_enabled=”off” button_one_letter_spacing__hover_enabled=”off” button_two_letter_spacing__hover_enabled=”off” button_bg_color__hover_enabled=”off” button_one_bg_color__hover_enabled=”off” button_two_bg_color__hover_enabled=”off”][\/et_pb_contact_field][et_pb_contact_field field_id=”Message” field_title=”Mesajul dvs.” field_type=”text” fullwidth_field=”on” _builder_version=”4.16″ global_colors_info=”{}” button_text_size__hover_enabled=”off” button_one_text_size__hover_enabled=”off” button_two_text_size__hover_enabled=”off” button_text_color__hover_enabled=”off” button_one_text_color__hover_enabled=”off” button_two_text_color__hover_enabled=”off” button_border_width__hover_enabled=”off” button_one_border_width__hover_enabled=”off” button_two_border_width__hover_enabled=”off” button_border_color__hover_enabled=”off” button_one_border_color__hover_enabled=”off” button_two_border_color__hover_enabled=”off” button_border_radius__hover_enabled=”off” button_one_border_radius__hover_enabled=”off” button_two_border_radius__hover_enabled=”off” button_letter_spacing__hover_enabled=”off” button_one_letter_spacing__hover_enabled=”off” button_two_letter_spacing__hover_enabled=”off” button_bg_color__hover_enabled=”off” button_one_bg_color__hover_enabled=”off” button_two_bg_color__hover_enabled=”off”][\/et_pb_contact_field][\/et_pb_contact_form][\/et_pb_column][et_pb_column type=”2_5″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.19.4″ text_font=”Kaushan Script||||||||” text_text_color=”#f0622a” text_font_size=”30px” header_font=”||||||||” background_layout=”dark” global_colors_info=”{}”]<\/p>\n Operatorul PDI 2023<\/p>\n [\/et_pb_text][et_pb_text _builder_version=”4.16″ text_font=”||||||||” global_colors_info=”{}”]<\/p>\n <\/span><\/p>\n <\/span><\/p>\n Adresa: Str. A. Panu nr. 13, Iasi<\/span> [\/et_pb_text][et_pb_text disabled_on=”off|off|off” _builder_version=”4.20.2″ text_font=”Kaushan Script||||||||” text_text_color=”#f0622a” text_font_size=”30px” header_font=”||||||||” background_layout=”dark” locked=”off” global_colors_info=”{}”]<\/p>\n Parteneri Media<\/p>\n [\/et_pb_text][et_pb_slider disabled_on=”off|off|off” _builder_version=”4.20.4″ _module_preset=”default” position_origin_r=”bottom_left” width=”200px” max_width=”200px” content_width=”200px” content_max_width=”200px” min_height=”100px” height=”100px” max_height=”100px” custom_margin=”0px||0px||false|false” custom_padding=”0px||0px||false|false” auto=”on” auto_speed=”3000″ global_colors_info=”{}”][et_pb_slide _builder_version=”4.20.2″ _module_preset=”default” background_enable_color=”off” background_image=”https:\/\/pdi.ro\/2023\/2022\/wp-content\/uploads\/2022\/05\/timpul_.jpg” background_enable_image=”on” background_size=”initial” custom_padding=”0px||0px||false|false” link_option_url=”#” link_option_url_new_window=”on” global_colors_info=”{}” sticky_transition=”on”][\/et_pb_slide][et_pb_slide _builder_version=”4.20.2″ _module_preset=”default” background_enable_color=”off” background_image=”https:\/\/pdi.ro\/2023\/2022\/wp-content\/uploads\/2022\/05\/medical-market_.jpg” background_enable_image=”on” background_size=”initial” custom_padding=”0px||0px||false|false” link_option_url=”https:\/\/issuu.com\/finwatch\/docs\/dermato?fr=sYWIzMjQ1MDUxNTY” link_option_url_new_window=”on” global_colors_info=”{}” sticky_transition=”on”][\/et_pb_slide][et_pb_slide button_text=”Click Here” _builder_version=”4.20.4″ _module_preset=”default” background_color=”RGBA(255,255,255,0)” background_enable_color=”on” background_image=”https:\/\/pdi.ro\/2023\/wp-content\/uploads\/2023\/04\/Logo-JURMED-RGB.jpg” background_enable_image=”on” background_size=”contain” link_option_url=”https:\/\/jurmed.ro\/” link_option_url_new_window=”on” global_colors_info=”{}” sticky_transition=”on”][\/et_pb_slide][\/et_pb_slider][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":" Prof. Dr. Daciana Elena Br\u0103ni\u0219teanuUniversitatea de Medicin\u0103 \u0219i Farmacie \u201cGrigore T. Popa\u201d Ia\u0219iSpitalul Clinic Universitar CF Ia\u0219iSimpozion SANDOZ Inova\u021bie continu\u0103 \u00een managementul onicomicozei Simpozion ACM Heliocare: foto-imunoprotec\u021bie dermatologic\u0103 3600 oral\u0103 \u0219i topic\u0103 Simpozion URIAGE Pruriced cu patentul PAR-2 REGUL, inova\u021bia Uriage \u00eempotriva pruritului Daciana Elena Br\u0103ni\u0219teanu Universitatea de Medicin\u0103 \u0219i Farmacie \u201cGrigore T. Popa\u201d Ia\u0219i, […]<\/p>\n","protected":false},"author":2,"featured_media":11595,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[12],"tags":[],"class_list":["post-11586","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-lectori"],"_links":{"self":[{"href":"https:\/\/pdi.ro\/2023\/wp-json\/wp\/v2\/posts\/11586","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pdi.ro\/2023\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pdi.ro\/2023\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pdi.ro\/2023\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/pdi.ro\/2023\/wp-json\/wp\/v2\/comments?post=11586"}],"version-history":[{"count":15,"href":"https:\/\/pdi.ro\/2023\/wp-json\/wp\/v2\/posts\/11586\/revisions"}],"predecessor-version":[{"id":13148,"href":"https:\/\/pdi.ro\/2023\/wp-json\/wp\/v2\/posts\/11586\/revisions\/13148"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pdi.ro\/2023\/wp-json\/wp\/v2\/media\/11595"}],"wp:attachment":[{"href":"https:\/\/pdi.ro\/2023\/wp-json\/wp\/v2\/media?parent=11586"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pdi.ro\/2023\/wp-json\/wp\/v2\/categories?post=11586"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pdi.ro\/2023\/wp-json\/wp\/v2\/tags?post=11586"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\nHeliocare: foto-imunoprotec\u021bie dermatologic\u0103 3600 oral\u0103 \u0219i topic\u0103<\/span><\/p>\n
\nPruriced cu patentul PAR-2 REGUL, inova\u021bia Uriage \u00eempotriva pruritului<\/span>
\nDaciana Elena Br\u0103ni\u0219teanu
\nUniversitatea de Medicin\u0103 \u0219i Farmacie \u201cGrigore T. Popa\u201d Ia\u0219i, Rom\u00e2nia
\nSpitalul Clinic Universitar CF Ia\u0219i, Rom\u00e2nia<\/p>\n
\nAcest simptom are cauze fiziologice sau patologice, intensitate de la discret\u0103 la sever\u0103, durat\u0103 de la ocazional\u0103 la cronic\u0103 \u0219i poate afecta corpul localizat sau generalizat.
\nDeoarece este manifestat \u00eentr-o multitudine de afec\u021biuni, afect\u00e2nd calitatea vie\u021bii pacien\u021bilor, este bine de \u0219tiut c\u0103 exist\u0103 produse dermato-cosmetice care pot fi recomandate pentru a reduce pruritul, de sine st\u0103t\u0103tor sau \u00een asociere cu alte tratamente.
\nURIAGE a dezvoltat gama Pruriced, cu patentul inovator PAR-2 Regul, Calamin\u0103, Ap\u0103 Termal\u0103 Uriage \u0219i p\u00e2n\u0103 la 96% ingrediente de origine natural\u0103.
\nPatentul PAR-2 Regul moduleaz\u0103 receptorul PAR2 care se implicat \u00een ambele c\u0103i ale pruritului \u2013 histaminic\u0103 \u0219i non-histaminic\u0103. Astfel, reduce expresia substan\u021belor pruriginoase \u0219i reduce pruritul.
\nCalamina este cunoscut\u0103 pentru propriet\u0103\u021bile sale calmante, hidratante, antipruriginoase, purificatoare \u0219i revigorante.
\nApa Termal\u0103 Uriage este o ap\u0103 izotonic\u0103, filmogenic\u0103, bogat\u0103 \u00een minerale \u0219i oligoelemente, activ\u0103 \u0219i cu propriet\u0103\u021bi unice de hidratare, calmare, vindecare \u0219i refacere a barierei cutanate.
\nPruriced este disponibil \u00een 3 formate de produs, potrivit pentru recomandare \u00een diferite tipuri de patologii sau nevoi de \u00eengrijire:
\n\u2022 Pruriced Crem\u0103 Calmant\u0103 \u2013 pentru prurit localizat sau generalizat, pe piele f\u0103r\u0103 p\u0103r, precum \u0219i prurit \u00een condi\u021bii diverse asociat pielii uscate.
\n\u2022 Pruriced Gel Calmant \u2013 pentru prurit generalizat sau localizat, \u00een zone cu p\u0103r, pliuri, zone extinse \u0219i zone intime externe.
\n\u2022 Pruriced SOS dup\u0103 \u00een\u021bep\u0103turi de insecte.
\nToate produsele pot fi recomandate de la nou n\u0103scu\u021bi p\u00e2n\u0103 la pacien\u021bii v\u00e2rstnici, \u00een func\u021bie de patologie.<\/p>\n
\nUniversity of Medicine and Pharmacy “Grigore T. Popa” Iasi, Romania
\nCF Iasi University Clinical Hospital, Romania<\/p>\n
\nThis symptom has physiological or pathological causes, variable intensity from discrete to severe, variable duration from occasional to chronic, and can affect the body locally or entirely.
\nIt is present in a multitude of conditions, affecting patients\u2019 quality of life. This is why it is important to know that there are dermato-cosmetic products that can be recommended to reduce pruritus, alone or associated with other treatments.
\nURIAGE has developed the Pruriced range, with the innovative PAR-2 Regul patent, Calamine, Uriage Thermal Water and up to 96% ingredients of natural origin.
\nPAR-2 Regul patent modulates the PAR2 receptor involved in the 2 pathways of pruritus \u2013 histaminic and non-histaminic. Thus, it reduces the expression of pruritic substances and reduces itching.
\nCalamine is known for its soothing, moisturizing, antipruritic, purifying and invigorating properties.
\nUriage Thermal Water is an isotonic, filmogenic water, rich in minerals and trace elements, active and with unique properties of hydrating, calming, healing and restoring the skin barrier.
\nPruriced is available in 3 product formats, suitable for recommendation in different types of pathologies or care needs:
\n\u2022 Pruriced Soothing Cream \u2013 for localized or generalized itching, on skin without hair, as well as itching in various conditions associated with dry skin.
\n\u2022 Pruriced Soothing Gel \u2013 for generalized or localized itching, in areas with hair, folds, extended areas and external intimate areas.
\n\u2022 Pruriced SOS after insect bites.
\nAll products can be recommended to patients of different ages, from newborns to elderly ones, depending on the pathology.<\/p>\n
\nBoala Venoasa Cronic\u0103: dincolo de semne…<\/span><\/p>\n
\nUniversitatea de Medicin\u0103 \u0219i Farmacie \u201cGrigore T. Popa\u201d Ia\u0219i, Rom\u00e2nia
\n\u015eef al Clinicii de Dermatologie, Spitalul Clinic CF Ia\u0219i, Rom\u00e2nia<\/p>\n
\nThe University of Medicine and Pharmacy \u201cGrigore T. Popa\u201d Iasi, Romania
\nHead of the Dermatology Clinic, CF Clinical Hospital Iasi, Romania<\/p>\n
\nLocul Ilumetri \u00een abordarea personalizat\u0103 a pacientului cu psoriazis<\/span><\/p>\n
\nDupixent \u2013 2 ani de success terapeutic \u00een Rom\u00e2nia<\/span><\/p>\n
\nDiferen\u021bierile moleculare ale inhibitorilor IL-23 influen\u021beaz\u0103 r\u0103spunsul \u00een tratamentul psoriazisului<\/span><\/p>\n
\nCOSENTYX \u2013 tratamentul complet al bolii psoriazice<\/span><\/p>\n
\nO nou\u0103 abordare terapeutic\u0103 oral\u0103 \u00een dermatita atopic\u0103 \u2013 inhibitorul Jak Olumiant<\/span><\/p>\n
\n1U.M.F. \u201dGrigore T. Popa\u201d Reumatologie Ia\u0219i, Rom\u00e2nia
\n2U.M.F. \u201dGrigore T. Popa\u201d Dermatologie Ia\u0219i, Rom\u00e2nia
\n3Dermatologie Bucure\u0219ti, Rom\u00e2nia<\/p>\n
\n1Rheumatology U.M.F. \u201dGrigore T. Popa\u201d Iasi, Romania
\n2Dermatology U.M.F. \u201dGrigore T. Popa\u201d Iasi, Romania
\n3Dermatology Bucharest, Romania<\/p>\n
\nAtopic dermatitis is one of the most common skin conditions, found in up to 20% of children and 2-10% of adults and has a chronic course, with a recurrent evolution. The treatment in atopic dermatitis must be adapted to the degree of severity, the main objectives being the suppression of inflammation and the restoration of the skin barrier function. It is important to note that severe atopic dermatitis can be treated with systemic, conventional, biological, or synthetic-targeted medication. Among the synthetic-targeted molecules is baricitinib, an intracellular inhibitor of the JAK-STAT pathway, with significant experience in rheumatology, in the indication of rheumatoid arthritis, which since 2020 is also indicated in moderate to severe atopic dermatitis in adult patients who are candidates for systemic therapy.<\/p>\n
\nSkyrizi – viitorul \u00een psoriazis este acum!<\/span><\/p>\n
\n1Sec\u021bia de Dermatovenerologie, Spitalul Clinic CF Ia\u0219i, Rom\u00e2nia
\n2Spitalul Clinic Colentina, Bucure\u0219ti, Rom\u00e2nia<\/p>\n
\nDe asemenea se vor detalia date pe termen scurt \u0219i pe termen lung care ofer\u0103 o imagine a terapiilor avansate utilizate \u00een practica clinic\u0103 \u00een ceea ce prive\u0219te eficacitatea \u0219i tolerabilitatea.
\nNu \u00een ultimul r\u00e2nd, \u00een simpozionul Abbvie se vor eviden\u021bia aspecte practice legate de managementul terapeutic modern al pacien\u021bilor cu psoriazis moderat \u0219i sever.<\/p>\n
\n1Department of Dermatovenerology, CF Iasi Clinical Hospital, Romania
\n2 Colentina Clinical Hospital, Bucharest, Romania<\/p>\n
\nShort-term and long-term data that provide a picture of advanced therapies used in clinical practice in terms of efficacy and tolerability will be presented also.
\nLast but not least, the Abbvie symposium will highlight practical aspects related to the modern therapeutic management of patients with moderate and severe psoriasis.<\/p>\n
\nBeneficiile de la A la Z pentru pacien\u021bii cu rozacee. Expertiza industriei farmaceutice rom\u00e2ne\u0219ti<\/span><\/p>\n
\nU.M.F. \u201cGrigore T. Popa\u201d Ia\u015fi, Rom\u00e2nia<\/p>\n
\nUn aspect important \u00een strategia terapeutic\u0103 destinat\u0103 rozaceei \u00eel constituie asocierea produselor dermatocosmetice. Linia Tinero\u00ae AZ are un rol important \u00een managementul rozaceei, prin controlul seboreei, refacerea func\u0163iei de barier\u0103 epidermic\u0103, sc\u0103derea inflama\u0163iei \u0219i reducerea eritemului.
\nLinia Tinero\u00ae AZ con\u0163ine trei produse (spum\u0103 pentru cur\u0103\u0163area bl\u00e2nd\u0103 a tenului, ser, crem\u0103 cu factor de protec\u0163ie solar\u0103) pe baz\u0103 de acid azelaic, un constituent natural al tegumentului. Acesta are un rol important \u00een tratamentul rozaceei, \u00een principal prin ac\u0163iunea antiinflamatorie \u0219i antioxidant\u0103. Date din literatur\u0103 \u00eei atribuie \u0219i o ac\u0163iune \u00eempotriva bacilului Oleronius.
\nGhidul de diagnostic \u0219i tratament al rozaceei, elaborat de SRD \u00een 2022, stipuleaz\u0103 c\u0103 \u00een func\u0163ie de gradul de seboree sau de iritare al fe\u0163ei, putem recomanda produse
\ndermatocosmetice sub form\u0103 de spum\u0103 (pentru ten cu grad redus de seboree) \u0219i produse pentru aplica\u0163ii \u00een timpul zilei, care con\u0163in ingrediente cu rol fotoprotector. \u00cen ceea ce prive\u015fte compozi\u0163ia, ghidul recomand\u0103 ingrediente cu ac\u0163iune antiiritant\u0103 \u0219i antiinflamatorie precum glicirizatul dipotasic \u0219i ceramidele, \u00eent\u00e2lnite de asemenea \u00een produsele din linia Tinero\u00ae AZ.<\/p>\n
\nU.M.F. \u201cGrigore T. Popa\u201d Iasi, Romania<\/p>\n
\nAn important aspect in rosacea therapeutic strategy is adding cosmeceuticals in therapeutical algorithm. Tinero\u00ae AZ line has an important role in the management of rosacea, by controlling seborrhea, restoring the epidermal barrier function, reducing inflammation and reducing erythema.
\nTinero\u00ae AZ line contains three products (foam for skin\u2019s gentle cleansing, serum and SPF hydrating cream) based on azelaic acid, a natural constituent of the skin. It has an important role in the treatment of rosacea, mainly through its anti-inflammatory and antioxidant action. It is also cited in literature azelaic acid\u2019s action against the Oleronius bacillus.
\nThe rosacea diagnosis and treatment guide, developed by the Romanian Dermatology Society in 2022, stipulates that depending on the degree of seborrhea or facial irritation, we can recommend cosmeceuticals like foam (for a low degree of seborrhea skin) and products for daytime applications, which contain ingredients with a photoprotective role. Regarding the composition, the guide recommends as well ingredients with anti-irritant and anti-inflammatory action such as dipotassium glycyrrhizate and ceramides which are also found Tinero\u00ae AZ line.<\/p>\n
\nBimzelx transform\u0103 visul de PASI 100 \u00een realitate<\/span><\/p>\n
\nA GUIDE to early intervention and disease modification in psoriasis<\/span><\/p>\n
\nProvoc\u0103ri \u00een dermatologia clinic\u0103 – focus \u00een dermatita atopic\u0103 \u0219i psoriazis<\/span><\/p>\n
\nSesiune de discu\u021bii: dermatita atopic\u0103 la adult \u2013 diagnostic \u0219i tratament<\/span><\/p>\n
\nSpeakeri: Carmen Curea1, A. Nicolescu2
\n1Spitalul Colentina Dermatologie Bucure\u0219ti, Rom\u00e2nia
\n2Dermatologie Bucure\u0219ti, Rom\u00e2nia
\n3U.M.F. \u201dGrigore T. Popa\u201d Dermatologie Ia\u0219i, Rom\u00e2nia<\/p>\n
\nCarmen Curea1, A. Nicolescu2
\n1Dermatology Colentina Hospital Bucharest, Romania
\n2Dermatology Bucharest, Romania
\n3Dermatology U.M.F. \u201dGrigore T. Popa\u201d Iasi, Romania<\/p>\n
\nTriAsorb – a ultra broad spectrum filter covering UVB UVA & HEV blue light up to 450nm<\/span><\/p>\n
\n\u2013 Doctor \u00een \u0219tiin\u021be medicale, teza de doctorat \u00een ACNEEA VULGARA (2004)
\n\u2013 Manager al Centrului de Dermatologie, Venerologie \u0219i Dermatocosmetologie \u201cDermaLux\u201d, din 2004 p\u00e2n\u0103 \u00een prezent
\n\u2013 \u0218ef sec\u021bie la Clinica Dermatologic\u0103 a Spitalului Clinic C\u0103i Ferate Ia\u0219i
\n\u2013 Competen\u021be \u00een anatomie patologic\u0103 cutanat\u0103 (Lyon, Fran\u021ba) \u0219i \u00een dermatocosmetologie
\n\u2013 Cursuri de supraspecializare \u00een Fran\u021ba, Lyon, Universite Lyon 2 (AFSA), cursuri europene de dermatoscopie, boala venoas\u0103 cronic\u0103, psoriazis, anti-aging, injectare de filere, laserterapie etc.
\n\u2013 Preocup\u0103ri deosebite pentru psoriazis: coordonator al Proiectului Na\u021bional Educa\u021bional \u201cPatologia psoriazisului\u201d, particip\u0103ri \u00een calitate de expert la \u00eent\u00e2lniri interna\u021bionale pe teme de psoriazis (Viena, Atena, Geneva etc.), articole publicate \u00een reviste na\u021bionale \u0219i interna\u021bionale, comunic\u0103ri orale, conferin\u021be, grupuri de lucru \u0219i workshop-uri pe tema psoriazisului
\n\u2013 Pre\u0219edinte al Asocia\u021biei Dermatologilor din Moldova, Pre\u0219edinte al manifest\u0103rii na\u021bionale cu participare interna\u021bional\u0103 \u201cPrim\u0103vara Dermatologic\u0103 Ie\u0219ean\u0103\u201d;
\n\u2013 Membru \u00een Comitetul Director al Societ\u0103\u021bii Rom\u00e2ne de Dermatologie
\n\u2013 Membru \u00een Grupul Interna\u021bional \u201cMedical Reporter\u2019s Academy\u201d, pe probleme de flebologie
\n\u2013 Membru al: Academiei Europene de Dermatologie, Academiei Americane de Dermatologie, Societ\u0103\u021bii Franceze de Dermatologie, Societ\u0103\u021bii Franceze de Flebologie, Societ\u0103\u021bii Interna\u021bionale de Dermatologie, Societ\u0103\u021bii de Dermatologie Investigativ\u0103, Societ\u0103\u021bii Rom\u00e2ne de Dermatopediatrie, Societ\u0103\u021bii Rom\u00e2ne de Dermatoimunologie, Societ\u0103\u021bii de Medici \u0219i Naturali\u0219ti
\n\u2013 Coordonator a peste 100 de cursuri de educa\u021bie medical\u0103 continu\u0103 \u0219i de cursuri postuniversitare
\n\u2013 Peste 400 de conferin\u021be, prelegeri \u0219i comunic\u0103ri orale sus\u021binute la manifest\u0103ri \u0219tiin\u021bifice, mese rotunde, conferin\u021be \u0219i congrese din \u021bar\u0103, nu doar de dermatologie
\n\u2013 Lector invitat la Congrese Interna\u021bionale ale: Societ\u0103\u021bii Europene de Dermatologie \u0219i Venerologie (EADV), Societ\u0103\u021bii Franceze de Flebologie (SFP), Uniunii Interna\u021bionale de Flebologie (UIP)
\n\u2013 Expert \u00een Boala Venoas\u0103 Cronic\u0103, \u00een Maladii Transmisibile Sexual, expert dermatolog \u00een solu\u021bionarea unor cazuri medico-legale
\n\u2013 Decan de Serie desemnat de c\u0103tre studen\u021bi, ca semn de respect \u0219i de recunoa\u0219tere a calit\u0103\u021bii de dasc\u0103l
\n\u2013 Implicare activ\u0103 \u00een activitatea de cercetare \u0219tiin\u021bific\u0103 (granturi de cercetare \u0219tiin\u021bific\u0103, proiecte na\u021bionale \u0219i interna\u021bionale, studii clinice, consultant \u0219tiin\u021bific, membru \u00een numeroase advisory board-uri etc.)
\n\u2013 Peste 230 de lucr\u0103ri publicate \u00een \u021bar\u0103 \u0219i \u00een str\u0103in\u0103tate, autoare a 23 c\u0103r\u021bi \u0219i capitole de c\u0103r\u021bi de dermatologie
\n\u2013 Absolvent\u0103 a Facult\u0103\u021bii de Medicin\u0103, U.M.F. \u201cGrigore T. Popa\u201d, Ia\u0219i, promo\u021bia 1991<\/p>\n<\/span><\/p>\n
Tel.: 0332.40.88.00-05<\/span>
E-mail: contact@pdi.ro<\/a>
<\/span>Website:\u00a0<\/span>www.eventernet.ro<\/a><\/p>\n